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ABSTRACT 
 
Idiopathic inflammatory myopathies (IIM), also known as myositis, are rare autoimmune 
diseases, characterized by proximal muscle weakness and inflammatory cells in skeletal 
muscle tissue. The most common subgroups are polymyositis (PM), dermatomyositis (DM) 
and inclusion body myositis (IBM). New subgroups have been recognized, such as immune- 
mediated necrotizing myopathy (IMNM) and the antisynthetase syndrome (ASS). 
Autoantibodies are common and some of them specific for myositis. The most frequent is the 
anti-Jo-1 autoantibody, which is associated not only with myositis but also with interstitial 
lung disease (ILD) and arthritis. The etiology of IIM is still unknown but environmental and 
genetic factors are believed to contribute to disease susceptibility. Accumulating data 
indicate a role of the type I interferons (IFNs) in myositis.	   The treatment of IIM 
(glucocorticoids and immunomodulatory drugs) has limited effect. New treatments are 
needed, thus increased understanding of molecular disease mechanisms in IIM is required. 
The overall aim of my thesis was to get an increased understanding of molecular mechanisms 
that are involved in IIM with a focus on the type I IFN system, autoantibodies and 
mechanisms that may induce immune reactivity, to be able to subclassify patients. 
Several new observations were made. Firstly, we found that line blot is a suitable serological 
test in myositis and is a reliable alternative to more time-consuming assays such as 
immunoprecipitation (paper I). Secondly, we concluded that smoking is associated with IIM 
patients who are either anti-Jo-1 autoantibody and/or HLA-DRB1*03 positive (paper II). 
These associations point towards a gene-environment interaction in the pathogenesis for IIM. 
Thirdly, we found that a high IFN score was not only associated with the subset DM, as 
previously reported, and IBM, but also with autoantibody monospecificity against RNA-
binding proteins or with autoantibody multispecificity (paper III). Furthermore, we identified 
IFN-α in sera as a trigger for activation of the type I IFN pathway in peripheral blood, which 
supports IFN-α as a possible target for therapy in these patients. Finally, we found that PM 
and DM are associated with dysregulation of endothelial progenitor cell (EPC) phenotype and 
function that may be attributed, at least in part, to aberrant IL-18 and type I IFN pathways 
(paper IV).  
In conclusion, this thesis confirms a role of the type I IFN system in myositis, especially in 
subgroups of patients, based on their autoantibody status, and implicates a relationship 
between the type I IFN system and endothelial disruption. Furthermore, smoking may be a 
trigger in the pathogenesis of IIM in genetic susceptible persons. However, the implication of 
our findings to disease prognosis and treatment remain to be determined. 
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1 INTRODUCTION 
 
1.1 IDIOPATHIC INFLAMMATORY MYOPATHIES 
Idiopathic inflammatory myopathies (IIM), also known as myositis, are rare chronic 
autoimmune diseases, characterized clinically by proximal muscle weakness and 
histologically by inflammation in skeletal muscle tissue. The most common subgroups in 
adults, classified on the basis of clinical and histopathological features are: polymyositis 
(PM), dermatomyositis (DM) and inclusion body myositis (IBM) [1] and in children, juvenile 
DM (JDM). However, new subgroups have been recognized, such as immune-mediated 
necrotizing myopathy (IMNM) [2] and the antisyntethase syndrome (ASS), due to the 
discovery of new myositis-specific autoantibodies (MSAs), associated with these distinct 
clinical phenotypes [3]. The etiology of IIM is still unknown but environmental and genetic 
factors are believed to contribute to disease susceptibility. The treatment of IIM, consisting of 
high-dose glucocorticoids and immunomodulatory drugs, has limited effect. New treatments 
are needed, thus increased understanding of molecular disease mechanisms in IIM is 
required. 
The first clinical description of PM was published by E. Wagner in 1886. Clinical 
manifestations described were stiffness, pain and limited motion of muscles, especially in the 
arm muscles and symmetrical edema. Lung affection and skin involvement were also 
described. PM had already been established at the time when DM was reported in 1891 by H. 
Unverricht. IBM was initially described by Chou in 1967 [4], but the term IBM was coined 
by Yunis and Samaha in 1971 [5]. 
This thesis concerns mainly adult patients with PM and DM. 
 
1.1.1 Classification and diagnostic criteria for idiopathic inflammatory 
myopathies 
1.1.1.1 Polymyositis and dermatomyositis 
The most commonly used criteria for diagnostic purposes and classification of PM and DM 
were proposed by Bohan and Peter in 1975 [6, 7]. The criteria consists of five variables 
(Table 1). 
The criteria of Bohan and Peter do not distinguish between IBM and PM. 
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Table 1. Bohan and Peter’s diagnostic criteria for polymyositis and  dermatomyositis 
1. Symmetric proximal muscle weakness of limb-girdle muscles and anterior               
neck flexors 
2. Elevation of serum skeletal muscle enzymes, creatine phosphokinase (CPK), 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate 
dehydrogenase (LD) and aldolase 
3. Electromyographic (EMG) indicating short, small, polyphasic motor unit 
potentials, fibrillations, positive sharp waves and insertional irritability and 
high-frequency repetitive discharges 
4. Muscle biopsy pathology with inflammatory exudates, regeneration with 
basophilia, type I and II fiber phagocytosis, large vesicular sarcolemmal nuclei 
and prominent nucleoli, muscle fiber atrophy in a perifascicular distribution and 
variation in muscle fiber size. 
5. Specific skin rash of dermatomyositis, including heliotrope rash and Gottron’s 
papules which are pathognomonic 
The diagnosis of PM is considered definite when four criteria (not including skin rash) are 
met. The diagnosis of PM is probable when three criteria (not including skin rash) are met 
and possible when two out of five criteria (not including skin rash) are fulfilled. The 
diagnosis of DM is considered definite when four criteria (including skin rash) are met. The 
diagnosis of DM is probable when three criteria (including skin rash) are met and possible 
when two criteria (including skin rash) are fulfilled. 
1.1.1.2 Inclusion body myositis 
Several diagnostic criterions for IBM have been proposed, first by Calabrese et al in 1987 [8], 
and then by Dalakas in 1991[1]. More recent and commonly used diagnostic criteria were 
proposed by Griggs et al in 1995 [9] (Table 2). 
Table 2. Grigg’s diagnostic criteria for inclusion body myositis 
1. Duration > 6 months 
2. Disease onset at age > 30 years 
3. Muscle weakness affecting proximal and distal muscles of arms and legs with at 
least one of the following features: 
a. Finger flexor weakness 
b. Wrist flexor > wrist extensor weakness 
c. Quadriceps muscle weakness 
4. Serum CPK < 12 times normal 
5. Muscle biopsy findings with: 
a. Inflammatory myopathy characterized by mononuclear cell invasion of 
non-necrotic muscle fibers 
b. Rimmed vacuoles in muscle fibers 
c. Intracellular amyloid deposits of tubulofilaments by electron 
microscopy 
6. EMG consistent with features of an inflammatory myopathy 
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The diagnosis of IBM is definite if muscle biopsy demonstrates the findings above, 
irrespective of clinical features. The diagnosis of IBM is possible even if muscle biopsy 
findings are negative, providing that clinical and laboratory findings are satisfied. 
New myositis classification criteria are currently under review by the EULAR and ACR 
criteria subcommittees, and thereafter these criteria will be submitted for publication. These 
new criteria are data driven, and based on clinical and histopathological data from patients 
and comparators from centres worldwide. A webcalculator has been designed to calculate a 
probability for the classification of myositis, based on the 16 variables included. Furthermore, 
the webcalculator will provide a subgroup of myositis if sufficient information is available 
[10]. 
1.1.2 Clinical manifestations and laboratory findings 
1.1.2.1 Skeletal muscle 
Most patients with PM or DM present with subacute or slowly progressive proximal muscle 
weakness of the shoulder and pelvic girdle, that is usually symmetric and is a major cause of 
disability in patients with myositis. Neck flexor muscle weakness can also occur. The patients 
experience difficulties in getting up from a chair, working with their arms above the head, 
walking stairs and difficulties in raising the head when supine. Besides muscle weakness, 
patients with PM or DM often suffer from decreased muscle endurance and muscle fatigue 
(exhaustion and tiredness). Muscle pain is less common than muscle weakness and fatigue. 
Typically the pain arises after a work load. Serum levels of muscle enzymes such as CPK, 
AST, ALT and LD are often increased. 
IBM patients differ clinically mainly through involvement not only of proximal thigh muscles 
but also of distal muscles. Involvement of the quadriceps muscle and of the deep finger 
flexors with weakness and muscle atrophy are often clues to diagnosis. In the beginning, it is 
not uncommon that IBM is misdiagnosed as treatment-resistant PM. Patients often present 
with falls because their knees collapse due to quadriceps muscle weakness, or they have 
difficulties in certain tasks, such as turning keys, owing to weakness of finger flexors. Neck 
flexors are often affected. Dysphagia may occur in 60 % of patients with IBM [11]. Disease 
progression is slow but steady and may resemble that of a muscle dystrophy. Most patients 
with IBM will require an assistive device, such as a walker or a wheelchair, within several 
years of onset. IBM patients rarely have muscle pain. Serum levels of CPK are usually only 
moderately elevated or may be normal. 
1.1.2.2 Extramuscular manifestations 
Extramuscular manifestations are common in PM and DM, but less frequent in IBM. The 
most common extramuscular manifestations are from the skin, affecting patients with DM. In 
both PM and DM the lungs, heart, joints and gastrointestinal tract may be affected. This 
indicates that PM and DM are systemic inflammatory diseases. Lung involvement, such as 
interstitial lung disease (ILD) [12, 13], and cardiac involvement [14] is associated with worse 
prognosis of survival. 
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Cutaneous manifestations. In approximately 60 % of classical DM, the cutaneous and muscle 
changes appear at the same time, but in 30% of classical DM patients the skin symptoms 
precede the muscle symptoms by weeks or months. There are also approximately 10-20 % of 
the DM patients that do not develop muscle weakness, for 6 months of longer, referred to as 
clinically amyopathic DM (CADM) or “dermatomyositis sine myositis” [15]. Although the 
muscle symptoms may respond to treatment, the cutaneous lesions often persist despite 
treatment, which could indicate that the molecular pathways are different in muscles and skin 
[16]. Characteristic skin changes of DM are Gottron’s papules (figure 1) and the heliotrope 
rash (figure 2) and they are considered pathognomonic manifestations of DM. Gottron’s  
papules are scaly, erythematosus plaques located over the extensor side of joints e.g. 
metacarpophalangeal joints and proximal-and distal interphalangeal joints of the hands and 
found in 60-80% of DM patients. Gottron’s sign is symmetrical, confluent, macular, 
violaceous erythema on the extensor side with a similar distribution as Gottron’s papules. The 
heliotrope rash is a violaceous periorbital oedema and found in 50% of DM patients. Other 
less specific cutaneous findings are V-sign (figure 3), shawl-sign (figure 4), holster sign, 
calcinosis, nailfold capillary changes and mechanic’s hands. 
 
Pulmonary manifestations. In PM and DM, pulmonary involvement is common and includes 
respiratory muscle weakness, aspiration pneumonia, interstitial ILD and fibrosis. ILD is 
recognized as a direct manifestation of PM and DM and occurs in 20-65% of all patients [17, 
18] and has been reported to be a major cause of death in patients with PM and DM and 
contributes to morbidity [13, 19]. The clinical manifestations of ILD may vary from 
asymptomatic to rapidly progressive dyspnea and to fatal outcome. Cough and dyspnea are 
the most common symptoms of ILD [17, 20] 
Cardiac involvement. Clinically manifest heart problems are relatively infrequent in patients 
with PM or DM. However, epidemiological studies on cardiovascular disease and IIM are 
rare. Subclinical cardiac involvement is not uncommon and the frequency varies depending 
on the methods used. Electrocardiography changes are the most common and include atrial 
and ventricular arrhythmias or alterations of the conducting system [21, 22]. Congestive heart 
failure and ischemic heart disease may also occur. In a recent study, traditional cardiovascular 
Figure 1. Gottron’s papules.  Figure 2. Heliotrope rash.             Figure 3. V-sign.          Figure 4. Shawl sign. 
Reprint with permission from Frontiers Media SA: Malik, A,Hayat G, Kalia JS, Guzman MA. Idiopathic 
Inflammatory Myopathies: Clinical Approach and Management. Frontiers in Neurology. 2016;7:64. 
doi:10.3389/fneur.2016.00064. 
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risk factors and coronary artery calcification were commonly seen in patients with PM and 
DM. However, coronary artery calcification was not associated with PM and DM per se, but 
rather with age and smoking in these patients [23]. 
Gastrointestinal tract involvement. The most common gastrointestinal tract symptom is 
dysphagia, due to weakness of the tongue, pharynx or esophagus and disturbed esophageal 
motility. Esophageal dysfunction occurs in 15-50 % of patients. 
Joint involvement. Arthritis is a common feature of myositis. It is often present at disease 
onset and may precede muscular symptoms of IIM [24]. The arthritis often present as 
symmetrical non-erosive polyarthritis, affecting mostly small joints of the hands, wrist and 
shoulders. Non-erosive polyarthritis is particularly common in the subset antisynthetase 
syndrome, a clinical phenotype characterized by the presence of myositis, antisynthetase 
autoantibodies, Raynaud’s phenomenon, ILD and mechanic’s hands and in overlap 
syndromes, where PM and DM occur in combination with one or several other rheumatic 
diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic 
sclerosis (SSc). 
Malignancies. There is an association between malignancies and IIM, particularly for DM 
where up to 20% may have a malignancy around time of DM diagnosis. Therefore, 
recommendations are to let all newly diagnosed DM patients undergo age-appropriate 
malignancy screening. Many types of malignancies have been associated with IIMs, but they 
generally reflect those malignancies found in age-and sex-matched populations, e.g. breast 
cancer, lung-and colorectal cancer for Western country cohorts [25, 26]. However, different 
studies have shown significant differences in degree of cancer risk in patients with IIM and 
this can partly be attributed to the different definitions of cancer-associated myositis (CAM) 
between different studies. CAM is usually defined based on close relationship in time 
between onset of myositis and diagnosis of cancer [27]. The most often used definition of 
CAM is the onset of cancer within 3 years of the diagnosis of myositis, but this definition has 
not been uniformly adopted. In recent years, studies have shown that patients with certain 
MSAs (anti-TIF1-γ autoantibodies and anti-NXP-2 autoantibodies) are at increased risk of 
malignancy [28-30]. Some studies suggest that anti-HMGCR autoantibodies also have an 
increased risk of malignancy, but further studies are needed. For further information about 
these autoantibodies, see chapter 1.1.9. 
Other manifestations. Systemic symptoms such as fatigue, morning stiffness, weight loss, 
Raynaud’s phenomenon and fever may also occur. 
1.1.3 Clinical outcome measures 
1.1.3.1 IMACS disease activity core set measures  
The International Myositis Assessment and Clinical Studies Group (IMACS), is an 
international consensus collaboration of health care providers and researchers with interest 
and experience in the IIMs. The goals of IMACS are to improve the lives of IIM patients 
through greater understanding of the pathogenesis of IIM and by discovering better therapies. 
IMACS has developed a three component core set outcome measure for adult and juvenile 
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myositis patients composed of myositis disease activity, myositis damage index and a health 
related quality of life assessment [31, 32]. In this thesis we used the first outcome measure, 
myositis disease activity. This core set consists of 6 domains: 
• Physician’s global disease activity assessment on a visual analogue scale (VAS) 0-
100 mm 
• Patient’s global disease activity assessment on a VAS (0-100 mm) 
• Manual muscle test (MMT) in 8 muscle groups on the dominant side (0-80) 
• Health assessment questionnaire (HAQ) (0.00-3.00) [33] 
• Assessment of serum levels of muscle associated enzymes (CPK, AST, ALT, LD) 
• Extramuscular global assessment on a VAS (0-100 mm) 
Improvement was defined according to IMACS, as 3 of any 6 measures improved by 20% or 
more, with no more than 2 worsened by 25% or more, which could not include MMT [32]. 
Worsening was defined by 30 % or more reduction in any 3 of 6 myositis disease activity 
core sets [34]. The changes at all time points were defined as changes compared to study 
start. 
1.1.4 Treatment 
The aims of the treatment are mainly to relieve the symptoms, slow disease progression, 
improve muscle function, reduce or prevent organ damage and make it possible for the 
patients to keep a good quality of life for as long as possible. Due to the lack of understanding 
of the disease mechanisms, there is no specific curing therapy for patients with IIM so far. 
Evidence based treatment for IIMs is extremely limited, as few trials have been conducted 
and due to the heterogeneity and rarity of these diseases, therefore the choice of treatment is 
often empirical. 
1.1.4.1 Glucocorticoid therapy 
Glucocorticoids are the first line of treatment in myositis patients and were introduced in the 
late 1940s, and had a major impact with reduced mortality and morbidity in myositis patients. 
There are only a few controlled trials of treatment in PM and DM patients and treatment 
recommendations are mainly based on clinical experience and open trials [35]. The exact 
mechanism of action of glucocorticoids are not fully understood, but involves mechanisms 
such as interference in binding or function of transcription factors involved in inflammatory 
pathways [36], thereby suppressing important cytokines such as tumor necrosis factor 
(TNFα) [37] and type I IFN [38, 39]. Glucocorticoids can also hinder the function of immune 
cells, such as proliferation, phagocytosis, antigen presentation and migration [40, 41]. In 
myositis, high doses of glucocorticoids, 0,75-1 mg/kg/day, are often given for several weeks, 
and then slowly tapered [35]. Many patients (70%) respond with improved muscle function, 
but few recover their former physical capacity [42] and side effects are common, such as 
hypertension, diabetes mellitus and osteoporosis [43, 44]. Less than 20% of the patients go 
into drug free remission. Most IBM patients do not respond to glucocorticoids or other 
immunosuppressive therapies [45]. 
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1.1.4.2 Other therapies  
Since glucocorticoids are not a sufficient treatment alone, many experts recommend 
combination therapies by including another immunosuppressive in order to improve the 
clinical response and reduce the need of glucocorticoids. The frequently used first line drugs 
are methotrexate at 15-20 mg/week or azathioprine at 2 mg/kg/day [46] . If these are without 
effect or not tolerated the recommended second line agents are: cyclosporine A, which has 
been found to be equally effective as methotrexate [47] or mycophenylate mofetil, as 
supported by case reports [48-50]. Patients (both PM and DM) refractory to first line, or 
above treatments, can be given intravenous immunoglobulins [35, 51, 52].  
1.1.4.3 Biological therapies 
The experience of treatment with biological agents in myositis is still limited.  
Biological agents have been available for more than two decades and the first agents 
available were tumour necrosis factor (TNF)α-blockers. The mechanism of action is by 
TNFα-receptor blockage and by inhibitory binding to transmembrane TNFα, thereby 
reducing inflammation. The efficacy of TNFα-blockade in myositis has only been evaluated 
in case reports and case series with diverse outcomes. In an uncontrolled study including 13 
patients with refractory myositis, 16 weeks of TNFα-blockade resulted in disease flares in 
some patients suggesting that TNFα is not a major molecular pathway in this phase of IIM 
disease [53].  
A recent review of 48 studies, assessed 458 refractory myositis patients treated with 
Rituximab (RTX) until July 2015. RTX is a chimeric monoclonal antibody binding the CD20 
antigen on the surface of B cells, resulting in depletion of CD20-positive B cells. In this 
review the rate of response to RTX was 78,3 % [54]. Furthermore, a study has shown that 
patients with autoantibodies (mainly anti-Jo-1 autoantibodies and anti-Mi-2 autoantibodies) 
were more likely to respond to RTX compared to autoantibody negative patients [54]. A very 
recent small (10 patients) randomized, double-blind, placebo-controlled clinical trial, showed 
that PM and DM patients who responded (defined by a consensus-driven definition of 
improvement) to RTX had higher levels of certain type I IFN gene expression (STAT4, 
IFNAR2, IRF4, IFI44) in muscle, and the responders had a greater decrease in the expression 
of these type I IFN genes than non-responders [55]. This suggests that the type I IFN 
signature is a biomarker of disease activity and also a predictor of therapeutic response.  
Interleukin-1 receptor blockade, anakinra, has been studied in a mechanistic study with 15 
patients during a 12 month follow up in patients with refractory PM/DM/IBM. Clinical 
improvement was noted in seven out of 15 patients, but the inflammation in muscle biopsies 
persisted [56]. One case reports has shown beneficial effect of anakinra in PM and DM [57]. 
Further studies are needed. 
Interleukin-6 receptor blockade, Tocilizumab, has shown beneficial effect concerning disease 
activity in a few case reports [58, 59]. 
An agent blocking T-cell co-stimulation, abatacept, has shown beneficial effect on clinical 
symptoms and on CPK levels in three case reports [60-62]. A pilot study with randomized 
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treatment delayed-start with abatacept including 20 patients with PM and DM, showed 
improvement according to the IMACS definition of improvement. The improvement was also 
significant for MMT8 and health-related quality of life physical component in 50 % of the 
patients, but further investigations on the effects of abatacept in myositis are needed 
(Lundberg, I et al, Arthritis Rheum, ACR abstract no 2361, 2015). 
IFN-blocking agents are on the market, and clinical trials with anti-IFNα monoclonal 
antibodies suggest beneficial effects in SLE [63, 64]. A randomised, double-blind, placebo 
controlled, dose-escalation, multicentre clinical trial was conducted to evaluate the effects of 
sifalimumab, an anti-IFN-α monoclonal antibody, in the blood and muscle of PM and DM 
patients by measuring neutralisation of a type I IFN gene signature following sifalimumab 
administration [65]. Both IFN-inducible transcripts (in muscle biopsies) and proteins (in 
peripheral blood) were suppressed following sifalimumab administration. Patients with 15% 
or greater improvement from baseline MMT scores showed greater neutralisation of the IFN 
gene signature than patients with less than 15% improvement in both blood and muscle. This 
trial included 51 patients, therefore these observations will require confirmation in a larger 
trial. 
Sera from 48 of the PM/DM patients from this trial were also collected, to compare the 
effects of sifalimumab and placebo on protein markers, such as IL-18, IL-2 receptor 
antagonist (IL2RA) and B cell activating factor (BAFF). All of these proteins showed 
reduced levels after sifalimumab administration, but this was not seen in the placebo group. 
Furthermore, there was an overexpression of these proteins in those patients with an elevated 
type I IFN signature at baseline. Down-regulation of IL2RA correlated with improved MMT-
8 in patients treated with sifalimumab [66]. 
In contrast to PM and DM, above-mentioned immunosuppressive drugs usually fail in IBM 
and currently there is no effective pharmacological treatment for IBM [67, 68] 
1.1.4.4 Physical exercise 
Earlier patients with PM and DM were advised against physical activity since it was believed 
to worsen the inflammation. The earliest two studies came in 1993, showing that exercise 
improved the muscle function, without clinically significant rises in serum levels of CPK 
[69, 70]. Further studies have shown that physical exercise improved strength, oxygen 
capacity, quality of life and that exercise is also safe to perform [71-73]. In a multicenter 
randomized controlled trial (RCT) from 2013, the effect of exercise in 23 established 
myositis patients was evaluated [74]. The trial revealed reduced disease activity in the 
exercise group compared to the control group. Another RCT, with recent onset PM and DM 
patients, supports the safety of exercise in these patients, i.e. no increased inflammation in 
muscle biopsies or increased CPK levels. However, no in between-group differences in effect 
of the exercise were shown [75]. In a pilot study, modest resistance exercise led to improved 
clinical performance and in muscle tissue there was a reduced expression of genes involved 
in inflammation and fibrosis [76]. Exercise has evolved as an important part of treatment of 
myositis patients. The amount of exercise and the intensity of the exercise program need to be 
adapted to each individual myositis patient. More studies to determine the optimal form of 
exercise in myositis patients are needed. 
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1.1.5 Epidemiology 
PM and DM are rare disorders with an overall incidence of approximately 2 to 10 new cases 
per million persons and year [77]. The variations reflect ethnical, geographic and inclusion 
criteria used in the studies [78-80]. The peak of incidence in adults is said to be between 50 to 
60 years of age, although other age groups may also be affected [81]. In a yet unpublished 
study from our research group, the estimated overall incidence of IIM was 11 per 1.000.000 
and year and the prevalence 14 per 100.000 in Sweden (Svensson, J. et al, personal 
communication). Furthermore, the incidence increased with age and peaked at the 50-79 year 
age groups. However, in earlier studies the incidence pattern of IIM is said to be bimodal in 
PM and DM with an initial peak in childhood before the age of 20 and another adult peak 
between 45-69 years in adults [82, 83]. The incidence sex ratio is 2:1 (female:male) and the 
incidence race ratio is 3-4:1 (Afro-American:white) [79, 84]. 
In a systematic literature review from 2015 (46 articles published between 1966-2013 were 
reviewed), the prevalence of IIM ranged from 2-34 per 100.000 inhabitans [85]. The 
differences in prevalence may be explained by methodological issues or that there may be 
regional or ethnical differences. The ratio between PM and DM varies in different parts of the 
world, although PM and DM are present all over the world. A latitude gradient has been 
observed with DM being more common closer to the equator [86, 87]. 
There have been few population-based studies in IBM and the incidence ranges from 2.2-4.9 
cases per million persons and year [88]. The mean age at diagnosis is more than 65 years and 
the incidence sex ratio is 1:2 (female:male) [89]. In a study from Norway from 2014, a 
prevalence of 35 per 1.000.000 was observed [90]. 
1.1.6 Etiology 
The cause of IIM is yet unknown. However, there is most likely an interplay between genetic 
susceptibility and exposures to certain environmental factors. Multiple factors such as 
immunologic, genetic and environmental (e.g. infections, drugs, smoking, hormonal factors, 
ultraviolet (UV) radiation and stress) probably contribute to disease susceptibility. 
1.1.6.1 Genetic association 
The known genetic risk and protective factors in myositis are common alleles at polymorphic 
immune response loci and vary depending on clinical phenotype. Genetic risk factors include 
polymorphisms of many genes that regulate responses to environmental agents, particularly 
human leukocyte antigens (HLA), cytokines and immunoglobulin agents [91]. Certain 
polymorphic loci, such as HLA DRB1*0301 and Gm 2 23 5,13 are risk factors for all of the 
major clinical groups. HLA DRB1*0301/*0501 and DQA1*0501 on chromosome 6 are the 
strongest known risk factors for myositis in Caucasians especially in patients with ILD and/or 
anti-aminoacyl-tRNA synthetase autoantibodies [92, 93]. HLA genes are the most 
consistently identified genetic factors associated with autoimmune inflammatory diseases. 
HLA genes code for antigen-presenting molecules that play important regulatory roles in 
immune activation. Genetic associations are stronger with phenotypes defined by 
autoantibodies and by phenotypes defined by clinical features, than with myositis as a whole. 
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Risk genes for one phenotype are often protective for another, possibly explaining the mutual 
exclusivity of many myositis subgroups [94]. Genetic factors for myositis also vary by age of 
onset, ethnicity and environmental exposure group [95]. A genome-wide association study in 
DM has confirmed the importance of the major histocompatibility complex (MHC) complex 
but also suggested non-MHC genetic features overlapped with other autoimmune diseases 
[96]. In the largest genetic study to date in IIM (2566 myositis patient and 15 651 controls), it 
was confirmed that PTPN22 and HLA, are the most strongly associated regions in IIM. 
Interestingly, STAT4, also reached a suggestive level of significance [97]. STAT4 is a 
susceptibility locus for many autoimmune diseases, and has been associated with DM in the 
Japanese population and is an important transcription factor for many genes involved in T 
cell differentiation. A risk variant of STAT4 has been shown to increase the sensitivity to 
IFNα in SLE-patients [98]. 
1.1.6.2 Infectious association 
Viral infections that have been associated with IIMs are hepatitis C [99-101], parvovirus B19 
[102], influenza viruses [103],  and coxsackie virus [104, 105]. Retroviruses such as human  
T cell lymphotropic virus (HTLV-1) and human immunodeficiency virus (HIV) [106-108] 
have been associated with myositis, but muscle biopsies have failed to show viral nuclei acid 
[109]. It has also been reported that bacterial infections, such as staphylococcus aureus and 
streptococci [110], can invade muscle and cause an acute syndrome, pyomyositis. Parasites 
such as schistosoma and trichinella can be associated with myopathies. Elevated titers of 
antibodies of borrelia and toxoplasma, have been found in myositis patients, even though the 
antigens cannot be found histologically in the muscle tissue from myositis patients [111, 
112]. Furthermore, mice infected with a parasite, trypanosoma cruzii, can develop a PM-like 
disease with similar histopatology [113]. In a recently accepted article by S. Barbasso 
Helmers et al, it was shown that subjects with preceding inflammatory lung disease, such as 
pneumonia, tuberculosis or sarcoidoisis tend to have an increased risk of developing myositis 
compared to those without. A history of gastrointestinal or respiratory symptoms, suggestive 
of infections, have been reported to precede the symptoms of muscle weakness and typical 
skin rash in JDM [114, 115].  
1.1.6.3 Drug association 
Many drugs, such as, statins, chlorochine, D-penicillamine and colchicines, can cause a 
myopathy which resembles myositis [116, 117]. However, the mechanism of drug-related 
myopathies is not understood, and whether they contribute to the development of IIM is 
unclear. 
1.1.6.4 UV-light association 
One environmental factor of interest in the pathogenesis of IIM is UV radiation. UV radiation 
has several immunomodulatory effects, such as triggering of cytokine production [118], 
regulation of surface expression of adhesion molecules [119], affecting cellular mitosis [120] 
and by inducing apoptotic cell death [121]. In DM, muscle and cutaneous manifestations 
have been shown to relapse more often in summer, whereas PM patients relapses was more 
evenly distributed during all four seasons, although lowest in summer [122]. DM is also more 
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frequent in countries around the equator than in countries on other latitudes [86, 87], 
supporting a role of UV radiation as an environmental factor that could contribute to disease 
onset. An association between UV radiation and anti-Mi-2 autoantibodies has also been 
shown [86]. Low serum levels of vitamin D have been reported in several autoimmune 
disorders, e.g. SLE [123], RA [124] and also in adult myositis [125], which suggest that 
vitamin D deficiency may be a risk factor for the development of autoimmune diseases 
including IIM. 
1.1.6.5 Smoking 
Tobacco smoking is a risk factor for several rheumatic diseases, such as SLE, RA and SSc. 
Smoking also affects both the outcome and course of rheumatic diseases. An association 
between smoking and dsDNA autoantibody production has been reported [126]. Furthermore, 
an association between smoking and an increased disease activity in SLE has been shown 
[127]. Smoking can predict the first cardiovascular event in SLE patients [128]. Tobacco 
smoking is a well established risk factor for the development of RA associated with 
rheumatoid factor (RF) positive but not with RF negative disease [129-131]. Tobacco 
smoking has also been associated with anti-cyclic citrullinated antibody (anti-CCP) positive 
but not anti-CCP negative RA [132]. Furthermore, a gene-environment interaction between 
smoking and HLA-DR shared epitope (SE) genes was present for the anti-CCP positive but 
not anti-CCP negative RA patients [132]. In affected subjects, exposure to tobacco smoking 
has also been associated with several measures of disease severity such as the presence of 
radiographic erosions, nodules, pulmonary disease and anti-RF-and anti-CCP autoantibodies 
[132-134]. Tobacco smoking increases the risk of digital ischemia and increases the severity 
of Raynaud’s phenomenon in SSc [135], and also increases the risk of atherosclerosis [136]. 
The effects of smoking on the immune system are complex and not fully understood. Several 
plausible hypotheses have been presented. Genetic susceptibility certainly may have a role. 
Smoking can cause tissue damage and increase apoptosis, induce inflammation and have an 
immunosuppressive effect [137]. 
Limited data are available on smoking in patients with IIM. In an abstract to American 
college of Rheumatology (ACR) from Schiffenbauer A. et al in 2015, data suggest that 
smoking in PM and DM Caucasian patients is a risk factor for developing ILD, anti-Jo-1 
autoantibodies and antisyntethase antibodies. In contrast, this was not seen in 
African/American PM/DM patients. This suggests that smoking can modulate serological and 
clinical status between different racial populations. The role of tobacco smoking for 
development of IIM has not been fully investigated, therefore this was something we wanted 
to study further (paper II).  
1.1.7 Pathogenesis  
Although IIMs were first described more than a century ago, many questions concerning the 
pathogenesis remain unclear. Muscle weakness, the most prominent symptom, is shared by 
all subsets of IIM, suggesting that some pathogenic mechanisms are shared. There are 
however some discrepancies, PM and DM often present with proximal muscle weakness and 
decreased endurance in proximal muscles, often without muscle atrophy, whereas in IBM the 
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weakness also involves distal muscle groups, with atrophy of thigh and finger flexor muscles. 
This suggests that some pathogenic mechanisms may differ between the subsets. 
The presence of frequently detected autoantibodies and the presence of T cells in muscle 
tissue in a majority of patients with myositis, indicate that immune mechanisms are involved, 
and that both T and B cells may have a pathogenic role in these diseases. 
Three major effector mechanisms have been proposed to be important for development of 
chronic muscle inflammation, muscle weakness and muscle fatigue. 
• direct effect of infiltrating leukocytes, mainly T cells and macrophages on muscle 
cells (cytotoxicity) [138, 139], promoting the production of autoantibodies from B-
cells.  
• indirect effects of molecules from the immune system [cytokines, for instance 
interferons (IFNs) and others] on muscle funtion and metabolism.  
• involvement of microvessels  and a disturbed microcirculation, leading to metabolic 
disturbances and reduced muscle function.  
T cells 
Due to prominent findings of cluster of differentiation (CD)4+ T cells and CD8+ T cells in 
muscle tissue of myositis patients, a role of T cells in disease mechanisms of myositis has 
been suggested. T cells may have direct myotoxic effects on muscle fibers [140], leading to 
necrosis and regeneration of muscle fibers promoting the expression of specific muscle 
autoantigens in regenerating muscle cells which may induce production of myositis related 
autoantibodies. T cells may also have indirect effects through production of molecules, such 
as cytokines, which can affect the muscle fiber phenotype, including the characteristic MHC 
class I expression on muscle fibers in myositis patients. In DM, the inflammatory infiltrate 
involves primarily CD4+ T cells, macrophages and a small number of B cells and plasma 
cells [138]. It localizes mainly in the perivascular and perimysial level. A pivotal role may be 
played by complement membranolytic attack complex that may be involved in damage of 
endothelial cells (ECs) with vascular injury and subsequent muscle inflammation [139, 141]. 
PM and IBM, however, are characterized by an endomysial mononuclear inflammatory 
infiltrate complex including CD8+ T cells, CD4+ T cells, macrophages and myeloid dendritic 
cells. CD8+ T cells and CD4+ T cells, may surround and invade non-necrotic muscle fibers 
that aberrantly express MHC class I, and may cause a perforin-mediated cytotoxic injury 
[142, 143]. In another subset of myositis, called IMNM, muscle fiber necrosis is seen as the 
dominating histopathological feature, but with few or no inflammatory infiltrates. The 
mechanisms for the fiber necrosis has not be clarified. However, the immune system is 
suggested to be involved, due to recently detected autoantibodies in this disease subset [2, 
144]. 
The CD28null  T cells, a subset of T cells, are another interesting observation in the 
pathogenesis of IIM. These are cells that lack the co-stimulatory molecule CD28, but have 
expression of other receptors associated with natural killer cells. They further have 
proinflammatory and cytotoxic features and are apoptosis resistant. It has been shown that the 
muscle-infiltrating T cells are mostly CD8+ CD28null  T cells and CD4+ CD28null  T cells in 
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PM and DM [145, 146]. These findings suggest that the CD28null  T cells are capable of 
inducing persistent inflammation and are capable of attacking muscle fibres.  
The role of the inflammatory cell infiltrates in causing muscle weakness is still unclear. From 
clinical observations it has been suggested that there is no correlation between the degree of 
inflammatory infiltrates and degree of muscle weakness [147-149]. This suggests that other 
mechanisms than T cell mediated cytotoxicity may contribute to muscle weakness. This 
could be by effects from molecules in the inflammatory milieu in the muscle. For instance 
this has been shown for the cytokine, TNF, which may affect muscle fiber contractility 
inducing muscle weakness [150].  
B cells 
High serum levels of BAFF, also known as B lymphocyte stimulator (BLyS), in myositis 
patients [151, 152], presence of B cells and plasma cells in muscle tissue [153] and 
autoantibodies in peripheral blood, support a role of these cells in the pathogenesis of 
myositis. This role is also supported by the beneficial effect of B cell depleting therapy by 
RTX, at least in a subgroup of patients with PM or DM. 
MHC class I 
The muscle cells in myositis patients frequently express the MHC class I antigen, 
independent of inflammatory cell infiltrates. This has been seen in early and late chronic 
phases of the disease [154]. This is a well known myopathological feature and can be used as 
a support for IIM in the diagnostic work-up in patients with muscle weakness [155]. MHC 
class I antigen is normally not expressed on differentiated muscle fibers. A role of MHC class 
I antigens in causing muscle weakness is supported by the observation that transgenic mice 
with specific up-regulation of MHC class I antigens on muscle fibers develop muscle 
weakness and histological and immunological features similar to human myositis patients 
[156]. MHC expression turns the muscle fibres into active participants in the cellular immune 
reactions, as it allows them to present antigen and activate T cells. One of the strongest 
inducers of MHC class I expression are the type I IFNs [157]. However, if muscle cells with 
MHC class I upregulation, present antigens to naive T cells to initiate a response against 
muscle antigens is not known. 
Dendritic cells 
Dendritic cells (DCs) are professional antigen-presenting cells that are involved in both the 
adaptive and innate immune systems. Their activation in peripheral tissue and lymphoid 
tissue leads to activation and migration of CD4+ T cells and CD8+ T cells and of B cells. 
DCs are of two types: myeloid (the conventional DCs) and plasmacytoid DCs (pDCs). The 
myeloid DCs play a key role in humoral immunity with activation of B cells and 
autoantibody production. The plasmacytoid DCs (pDCs) produce type I interferon (IFN) and 
have a key role in the innate immunity. For further information about IFNs, see chapter 1.1.8. 
 
 
 14 
HMGB1 
High mobility group box 1 (HMGB1) is a ubiquitous non-histone protein present in the 
nucleus of cells. It binds to DNA and helps regulate transcription and chromatin structure. 
When cells die HMGB1 can translocate from the nucleus to the cytosol and be released out of 
the cells and mediate chemotaxis, cytokine induction, tissue damage and affect fiber 
contractility. Recent studies have reported cytoplasmic HMGB1 expression in inflammatory 
cells, endothelial cells and also in muscle fibers of patients with myositis, suggesting a 
possible role of HMGB1 in the pathogenesis of myositis [158, 159]. HMGB1 has been found 
to reversibly induce MHC class I expression on muscle fibres and irreversibly impair Ca2+ 
release from the sarcoplasmic reticulum (SR) during induction of fatigue, indicating a direct 
effect of HMGB1 on generation of muscle force [159].  
Cytokines 
Several cytokines, such as interleukin (IL)-1 and IL-15 have been studied, in the disease 
pathogenesis. In a study with 15 patients with refractory myositis, 7 responded to IL-1 
receptor blocking, with improvement according the IMACS definition of improvement. 
However, no difference in IL-1 expression was seen in muscle tissue, before and after 
treatment with IL-1 receptor blocking, questioning the role of IL-1 in the pathogenesis of 
myositis [56]. However, larger studies are needed. In another study, myositis patients with a 
high number of IL-15 expressing cells in muscle tissue had less improvement in muscle 
performance after treatment with immunosuppressive agents for a median of 8 months and 
this persisted after 5 years [160]. This might suggest that IL-15 may have a role in chronic 
muscle inflammation and IL-15 may be a possible new target for treatment in subgroups of 
PM/DM. T helper (TH) 17 cell, preferentially produces IL-17. The differentiation of TH17 
cells depend on IL-6, IL-23 and transforming growth factor (TGF)-β. All these cytokines are 
locally produced by macrophages, monocytes, endothelial cells and dendritic cells. Serum 
levels of IL-15 and IL-17 have been shown to be higher in IIM patients than in healthy 
controls (HCs), and a strong correlation between IL-15 and IL-17 in DM was shown, 
suggesting a role of these cytokines in the pathogenesis of IIM [161].  
IL-18 is a TH1 inflammatory cytokine, mainly produced by antigen presenting cells (APCs). 
It is over-expressed in endomysial areas in PM and in perivascular areas in DM [162].  Serum 
IL-18 levels have been shown to be elevated in patients with DM and was associated with 
ILD complication [163]. Furthermore, a study has shown high serum levels of IL-18 in both 
PM and DM [162]. In addition, IL-18 was overexpressed in muscle biopsies from patients 
with PM and DM. ECs, smooth muscle cells (i.e. cells of the arterial wall) and CD8+ T cells 
expressed a high content of IL-18 receptors. These findings suggest a dysregulation of the IL-
18/IL-18 receptor pathway, which may be a pathogenic mechanism in IIMs. Also, in patients 
with SLE, IL-18 has been reported with elevated serum levels. The IL-18 levels correlated 
with disease severity and the presence of lupus nephritis [164, 165]. The inflammasome is a 
cytosolic multiprotein platform, whose assembly results in rapid activation of caspase-1, the 
enzyme responsible for generation of the active forms of IL-1β and IL-18. Type I IFN have 
been proposed to have a regulatory role in inflammasome activity in SLE patients, because 
the IFN-α responsive inflammasome scaffold absent in melanoma-2 (AIM2) (a cytoplasmic 
receptor for dsDNA) activates caspase-1. Caspase-1 also appears to be regulated by IFNs, 
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because the IFN-regulated transcription factor IRF-1 is essential for caspase-1 transcription 
and activation of IL-18 in response to IL-12 administration [166, 167]. IL-18 levels have 
been correlated with intima media thickness and increased vascular stiffness in men without 
evidence of coronary artery disease, suggesting a role of IL-18 in early stages of 
atherosclerosis development [168]. If IL-18 has a role in the pathogenesis of myositis is still 
unclear, and will need further investigations. A potential role of IL-18 and type I IFNs in 
myositis is discussed in paper IV. 
Vasculopatic mechanisms 
Another pathogenic mechanisms in IIM patients could possibly be explained by involvement 
of microvessels. A decreased number of capillaries in muscle biopsies has been reported in 
DM patients compared to healthy individuals, even in early cases without detectable 
inflammatory infiltrates [169]. A recent study from our research group has shown that a loss 
of capillaries is seen in early disease without inflammatory infiltrates in both PM and DM 
patients [170]. This finding correlated to an upregulated expression of the angiogenic factor, 
vascular endothelium growth factor (VEGF) in muscle fibres, suggesting that local muscle 
hypoxia could be a contributing factor to the impaired muscle function seen in myositis 
patients [170]. It has been demonstrated that ECs of the microvessels in muscle tissue from 
PM and DM patients are morphologically changed and express activation markers such as the 
proinflammatory cytokine IL-1α, the intercellular adhesion molecule (ICAM)-1, and vascular 
cell adhesion molecule (VCAM)-1. The phenotypic changes of the capillaries were related to 
the clinical signs of muscle weakness indicating a role of the microvasculature in the 
mechanisms causing the clinical symptoms [148]. 
Non-immune mechanisms 
The degree of inflammation in skeletal muscle is not always correlated to disease severity. 
Some patients do not respond to anti-inflammatory treatment and the clinical disease can 
progress, even though inflammation declines [147-149, 171]. This suggests a potential role 
for non-immune mechanisms in the pathogenesis of IIM, such as hypoxia, endoplasmic 
reticulum (ER) stress and autophagy.  Hypoxia can induce muscle weakness through reduced 
levels of phosphocreatine and ATP and production of adhesion molecules and 
proinflammatory cytokines and HMGB1 [172]. Hypoxia is also strictly connected with ER 
stress and/or impaired autophagy. ER stress is generated when accumulation of unfolded or 
misfolded proteins accumulate in the ER. Since several proteins that bind and/or regulate 
calcium homeostasis exist in the SR, a specialized form of ER, unfolded or misfolded 
proteins can cause muscle fatigue, by reducing Ca2+ release from SR [173]. A potential 
inducer of ER stress in IIM is the upregulation of MHC class I in muscle fibers. The ER 
stress can result in NF-κB activation that promotes the transcription of cytokine genes and 
thereby induces a self-sustaining inflammatory response that contributes to muscle damage 
[174].  
Autophagy is a very important process for removing unnecessary cellular material by 
degradation to lysosomes. If this does not work properly, it can induce autophagic celldeath. 
This mechanisms may be particular important for IBM [175]. 
 16 
There are several ways to learn about the pathogenic mechanisms in human diseases, through 
studies on animal models, through in vitro studies of tissue or cell cultures and from studies 
of the disease course and the target organs during therapies targeting distinct mechanisms or 
molecules. Although investigators have previously developed several spontaneous (genetic) 
and induced animal models possessing some features of IIM [176], none of these models 
fully reproduces human disease. A very exciting antigen-induced model of IIM to emerge 
over the last several years is based on immunization with the murine form of histidyl-tRNA 
synthetase (Jo-1). Mice immunized with murine Jo-1 developed a combination of 
inflammation of muscle and lungs, that replicates features of the human anti-synthetase 
syndrome [177].  
It has become increasingly important that the pathogenesis of IIMs is explored in detail so 
that more targeted and specific therapies, that are likely to be more effective and safe than the 
therapies that we have today, may be developed. 
In the following parts the autoantibodies, the inflammatory molecules (type I IFNs), the 
autoantibodies and endothelial progenitor cells (EPCs)/ECs, that were investigated in this 
thesis, are introduced in more detail regarding their basic properties and potential role in the 
pathogenesis of myositis. 
1.1.8 Interferons 
In England, the Briton Alick Isaacs and the Swiss Jean Lindemann, first characterized IFN in 
1957, to signify a protein, that was originally defined by its capacity to interfere with viral 
replication in cell cultures [178]. They noticed that cells already infected with a virus 
appeared to be resistant to infection by other viruses for a certain period of time. The first 
infection was said to “interfere” with (inhibit) the second. The protein isolated from these cell 
cultures was therefore given the name interferon (IFN).  
The IFNs are a group of non-antibody proteins, the so called cytokines, that act as mediators 
between cells. TNFα and ILs are other examples of cytokines. Cytokines in general are 
typically not stored as preformed proteins, rather their synthesis is initiated by gene 
transcription and their mRNAs are short lived, when immune response is needed. Therefore, 
the cellular response to cytokines is slow (hours).  
There are three types of IFNs, type I, type II and type III, based on their structural features, 
receptor usage and biological activities. The type I IFNs are the largest family that can be 
divided into 5 classes (IFNα, -β, -ω, -ε, and κ), of which IFN-alpha (IFNα) can be further 
divided into 12 subtypes encoded by 13 genes clustered on chromosome 9. The IFNα is a 
protein consisting of 165 amino acids without a glucose unit that is maintained in its three-
dimensional loop structure by two disulfide bridges. The type I IFNs bind to the same 
heterodimeric type I IFN receptor (IFNAR), consisting of two membrane spanning 
polypeptide chains, IFNAR1 and IFNAR2. The type II IFN, which sole member is IFN-
gamma (IFNγ), binds to the IFNγ receptor, IFNGR, a receptor complex, which consists of 
IFNGR1 and IFNGR2 chains. Type III IFNs (discovered in 2003) consists of IFN-lambda 
(IFN-λ1, λ2, λ3), also known as interleukin-28A/28B/29, and mediates their biological 
activities through the receptor, IFNλR1. Type I, II and type III IFNs activate the same 
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intracellular signaling pathway (of which the Janus kinase signal transducer and activator of 
transcription (STAT) pathway are the best characterized [179] and share many of the same 
biological activities. However, IFNARs are broadly expressed on most celltypes, whereas the 
IFNλ- receptors are largely restricted to cells of epithelial origin. 
Most types of cells can produce small amounts of type I IFN, but the principal type I IFN 
producer is a phenotypically and functionally distinct subset of DCs, the pDCs. The pDCs 
represent 0.2-0.8% of peripheral blood mononuclear cells (PBMCs) in both humans and mice 
[180]. They selectively express toll-like receptors (TLRs), such as TLR7 and TLR9, and are 
specialized in rapidly secreting massive amounts of type I IFN following viral stimulation. 
pDCs can promote the function of natural killer cells, B cells, T cells, and myeloid DCs 
during an antiviral immune response. At a later stage of viral infection, pDCs differentiate 
into a unique type of mature dendritic cell, which directly regulates the function of T cells 
and thus links innate and adaptive immune responses. The type I IFN genes are strictly 
regulated and normally almost no IFNα production can be detected in healthy individuals. 
The type I IFN is rapidly produced during viral invasion and constitutes our major defense 
system against viral infections. Furthermore, bacterial products [181] and autoantibody-
nucleic acid complexes have been shown to trigger pDCs production of IFNα [182]. Type I 
IFNs combat viruses both directly by inhibiting virus replication in the cells and indirectly by 
stimulating the innate and adaptive immune responses. The direct antiviral activity of type I 
IFNs is exerted by a number of different mechanisms, e.g. blockage of viral entry into the 
cell, control of viral transcription, cleavage of RNA, and preventing translation. In addition to 
the direct effects, type I IFN induces general activation of immune cells. For instance, type I 
IFN induces DC maturation and activation, with increased expression of chemokines and 
chemokine receptors, as well as co-stimulatory molecules [183]. IFNα has been shown to 
have many effects on the endothelium. IFNα has been shown to mediate dysfunction in 
EPC/circulating angiogenic cell (CAC) differentiation in SLE [184]. From the cancer 
literature it has been shown that IFNα is a potent antiangiogenic factor [185], inhibits EC 
invasion and migration and downregulates proangiogenic molecules [186]. Furthermore, type 
I IFNs have an inhibitory effect on bone marrow precursors [187]. However, the exact 
pathways in which IFNα inhibits angiogenesis are not well known. Type I IFNs are known to 
induce MHC class I expression. Furthermore, the co-localization of muscle fibres with 
expression of MHC class I and infiltrating immune cells expressing IFNα/β/γ proteins that 
has been described [157], strengthens the view that type I IFNs indeed are the inducers of 
MHC class I expression on muscle fibres, and that possibly IFNγ acts as an additional 
stimulator. However, discordant results have been published in regards to IFNγ expression in 
IIM. In regards to IFNβ, less data is currently available. Another role of type I IFNs is to 
promote the development of helper T cells along the Th1 pathway, and cytotoxic T cells are 
stimulated by type I IFNs. Type I IFNs can also cause B cell activation, differentiation, 
antibody production, and Ig isotype class switching. They also influence cell communication 
and are involved in the breakdown of unstable cellular messenger RNA, which plays an 
important role in the retardation of the uncontrolled division of tumor cells. IFNα is therefore 
used against malignant diseases, such as malignant melanoma and lymphomas.  
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Another role of the type I IFNs that has been suggested in SLE, is the interaction with 
neutrophils and the forming of neutrophil extracellular traps (NETs). In SLE there is a 
relationship between IFNα and NETosis. NETosis is a form of death in neutrophils in which 
nuclear material is extruded from the cell forming NETs to kill extracellular bacteria, viruses 
and parasites [188]. NETs contain decondensed DNA chromatin, granular and cytoplasmic 
proteins and histones. A variety of stimuli can trigger NETosis such as immune complexes, 
pathogens, IFNα and endothelial cells [189, 190]. NETs can activate pDCs to produce IFNα 
[189], and IFNα in turn can stimulate additional NETosis. Some components of NETs can 
directly injure ECs [191]. However, the removal of NETs should be closely regulated and 
failure to do so can cause tissue damage and may provide a new source of autoantigens and 
may be involved in SLE pathogenesis, and perhaps also in IIM which needs to be addressed 
in future studies. One first report concerning NETs formation in myositis has been performed 
[192]. Compared with healthy controls (HCs), PM and DM patients exhibited a significantly 
enhanced capacity for inducing NETs and NETs could not be degraded completely because 
of decreased DNase I activity in PM and DM patients, especially in patients with ILD. 
These findings suggest that abnormal regulation of NETs may be involved in the 
pathogenesis of PM and DM. Glucocorticoids seem to improve DNase I activity. Although 
NETs formation is excessive in vitro, NETs formation in vivo remains unknown in PM and 
DM. 
In recent years, genomic studies have shown marked overexpression of type I IFN inducible 
genes in the peripheral blood of patients with different autoimmune diseases such as SLE, 
DM, PM, multiple sclerosis, RA, SSc and Sjögren’s syndrome [193-197]. In SLE and SSc, 
immune complex (IC)-containing DNA or RNA are taken up by pDCs through Fc-receptors, 
where triggering of certain intracellular TLRs initiate down-stream signaling, which 
eventually results in transcription of type I IFN genes [198]. ICs containing DNA and RNA 
have the capacity to activate pDCs and RNA-containing ICs that trigger TLR7 seem to be 
especially potent as IFNα inducers [199]. In SLE there is a correlation between serum IFNα 
activity and presence of autoantibodies against RNA-binding proteins [200]. For further 
associations between type I IFNs and SLE and endothelial cells, see chapter 1.1.10. An 
activated type I IFN pathway has also been proposed to be involved in the pathogenesis of 
IIM, particularly in the DM subgroup, but the mechanisms driving the type I IFN pathway 
has not been clarified. Early evidence of an overactived innate immune system in DM was 
seen in 2005, when a strong IFN-inducible gene expression was detected in muscle and skin 
tissues of patients with DM [194]. In the following years, several groups have studied the IFN 
signature in muscle tissue and in peripheral blood in patients with myositis and from later 
reports the IFN signature has been linked to both DM and PM [193, 194, 201]. Case reports 
on development of PM/DM during IFNα/β therapy have been published [202, 203]. In one 
study, serum levels of IFNβ, measured by enzyme-linked immunosorbent assay (ELISA), but 
not IFNα, where shown highly associated with DM [204]. Another study showed increased 
IFNβ transcripts in PM and DM muscle [205].  In JDM a correlation was shown between 
presence of autoantibodies against RNA-containing autoantigens and serum IFNα activity 
and the capacity to generate interferonogenic ICs [206]. Upregulation of IFN-inducible genes 
has also been observed in the skin of patients with DM [207, 208] and the presence of pDCs 
within the epidermis of DM skin suggests that the IFN-mediated processes may take place in 
the skin, as well as in the muscles of these patients by mechanisms other than the IC-
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mediated mechanisms discussed above [209]. Furthermore, increased numbers of pDCs in 
muscle biopsies from patients with DM and JDM have been shown [210, 211]. However, 
there are contradictory results regarding correlation between the IFN signature in peripheral 
blood cells of IIM patients and disease activity [193, 212-214], which could be reflected by 
the fact that different IFN assays have been used in the different studies and that the 
definition of disease activity differed between the studies. The inducer of the type I IFN 
system in patients with IIM has not been clarified, but there is a suggestion of viral infections 
although this has not been confirmed. A subgroup of patients with PM and DM with anti-Jo-1 
or anti-Ro52/60 autoantibodies sera together with RNA, induced IFNα production in 
peripheral blood cells [215], suggesting that these antibodies may serve as endogenous IFN 
inducers in pDCs similarly as has been reported for antibodies against RNA binding proteins 
in patients with SLE. These observations also suggest that there may be a role for the type I 
IFN system not only in DM, but also in other subtypes of myositis, where patients have 
antibodies against RNA or RNA-binding proteins and that autoantibodies may have a role in 
driving the type I IFN pathway in subsets of patients with IIM. 
1.1.9 Autoantibodies 
One of the most important characteristics of IIM and of other systemic autoimmune diseases, 
is the immune response to self-antigens, manifested by the production of autoantibodies that 
target either nuclear or cytoplasmic components of the cell, involved in gene transcription, 
protein translocation and antiviral responses. Whether autoantibodies are simply 
epiphenomena or directly linked to pathogenesis remains unclear. In many autoimmune 
diseases, autoantibodies may be present several years before disease onset [216, 217]. This 
has also been reported in occasional individuals with IIM, indicating a role of autoantibodies 
in the initiation of the disease [218]. However, the mechanism for this is yet unknown. In 
myositis, autoantibodies may contribute to the disease mechanism, by direct damage to the 
cell that carries the antigen, via antibody-dependent cellular cytotoxicitiy or complement 
activation. Autoantibodies can also form ICs with the autoantigen and contribute to 
inflammation via activation of Fc-receptor-expressing cells or via the complement system. 
Over the past 40 years several autoantibodies have been discovered that are associated with 
IIM.  In recent years it has become even more apparent that autoantibodies have a role in 
distinguishing between subtypes of myositis patients and clinico-serological classifications 
have been proposed [219]. Myositis autoantibodies can be categorized into myositis-specific 
autoantibodies (MSAs) and myositis-associated antibodies (MAAs). MSAs are exclusively 
found in IIM and correlate with distinct clinical manifestations and genotypes [92, 219]. The 
most prevalent MSA is the anti-Jo-1 autoantibody (antihistidyl-tRNA synthetase). Eight anti-
aminoacyl-tRNA syntethase autoantibodies (ARSs) are known to date. The other ARSs 
identified are anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS, anti-Ha (YRS) and anti-Zo. 
Together with the other traditional MSAs, these antibodies can be identified in 40-50% of 
adult myositis patients. Other traditional MSAs are anti-SRP and anti-Mi-2. More recently, a 
number of novel MSAs have been identified, including anti-TIF1-γ (p155/140) anti-SAE, 
anti-MDA5 (CADM-140), anti-HMGCR and anti-NXP-2. When including these novel 
MSAs, it is now possible to identify a positive MSA or MAA in about 80 % with PM and 
DM [3]. In contrast, MAAs (i.e. anti-Ro52, anti-Ro60, anti-PM/Scl, anti-La, anti-U1RNP and 
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anti-Ku) are commonly found in patients who have features of other connective tissue disease 
(CTD), particular in overlap with systemic sclerosis. For target autoantigens and frequencies 
of MSAs/MAAs see table 3. For detection procedures see chapter 4.2. 
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Figure 5. Myositis autoantibodies and their key clinical associations. IBM, inclusion body myositis; CTD, 
connective tissue disease; SRP, signal recognition particle; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase; TIF1, transcription intermediary factor 1; NXP-2, nuclear matrix protein 2; MDA5, melanoma 
differentiation-associated gene 5; SAE, small ubiquitin-like modifier activating enzyme; 5NT1A, cytosolic 
5'nucleotidase 1A; Mi-2, nucleosome-remodelling deacetylase complex; Jo-1, histidyl-tRNA synthetase; PL7, 
threonyl-tRNA synthetase; PL12, alanyl-tRNA synthetase; OJ, isoleucyl-tRNA synthetases; EJ, glycyl-tRNA 
synthetase; KS, asparaginyl-tRNA sythetase; Zo, phenylalanyl-tRNA synthetase, Ha; tyrosyl-tRNA synthetase; 
snRNP, small nuclear ribonucleic protein. Reprinted with permission from John Wiley & Sons, Inc: Betteridge Z, 
McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 
2016;280(1):8-23. 
 
1.1.9.1 Myositis-specific autoantibodies (MSAs) 
MSAs are disease serological markers, nearly always mutually exclusive and closely 
associated with distinct disease subsets, making MSAs important diagnostic biomarkers 
(figure 5). Their detection in the early phase of the disease might be helpful in the prediction 
of clinical course and disease prognosis. 
Anti-aminoacyl-tRNA syntethase autoantibodies (ARSs) 
The ARSs target the aminoacyl-tRNA syntethases which catalyze the binding of amino acids 
to the corresponding tRNAs, so that the amino acid can be incorporated into a growing 
peptide chain. Each amino acid has a separate aminoacyl-tRNA synthethase and 
autoantibodies targeting 8 of the 20 aminoacyl-tRNA synthetases have been identified. The 
most common of these is the anti-Jo-1 antibody (anti-histidyl-tRNA syntetase), which is 
found in about 20% of adult IIM patients. The remaining antisynthetase autoantibodies: anti-
PL-12 (alanyl), anti-PL-7 (threonyl), anti-EJ (glycyl), anti-OJ (isoleucyl), anti-KS 
(asparginyl), and the more recently identified anti-Ha (YRS) (tyrosyl) and anti-Zo 
(phenylalanyl) - have been collectively described in a further 20%- 30% of patients, and the 
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frequency of each individual autoantibody is between 1% and 5% [219]. With a few 
exceptions, each antisynthetase-positive patient develops autoantibodies to only a single 
aminoacyl-tRNA synthetase. Patients with these autoantibodies are classified as having the 
antisynthetase syndrome (ASS) when associated with clinical manifestations of myositis, 
ILD, non-erosive arthritis, mechanic's hands, Raynaud phenomenon, and fever [220, 221]. 
Some patients also have a DM rash. One of the most frequent symptoms, contributing to high 
morbidity and mortality, is ILD. It has been reported that between 67 and 100% of ASS 
patients are affected by ILD [222-224]. 
Anti-Jo-1 autoantibodies 
Support for the role of anti-Jo-1 autoantibodies in the pathogenesis in IIM are: early 
observations that these autoantibodies are present at disease onset and can even precede the 
development of myositis symptoms [218], anti-Jo-1  positive sera may induce type I IFN 
production by pDCs [215] and anti-Jo-1 positive serum levels correlate with disease activity 
[225]. Additionally, in a conditional MHC class I mice model, mice developed myositis-like 
disease and autoantibodies to the Jo-1-autoantigen [156]. Furthermore, MHC class I as well 
as type I IFN-induced genes are highly expressed in muscle fibres from myositis patients in 
comparison to normal muscle [157]. Since type I IFN are strong MHC class I inducers [226], 
one mechanism by which anti-Jo-1 autoantibodies may mediate pathogenesis is via the IFNs, 
although whether anti-Jo-1 autoantibodies have a pathogenic role in disease mechanisms or 
are merely epiphenomena is still under debate. 
Anti-SRP autoantibodies 
Autoantibodies to the signal recognition particle (SRP) were first demonstrated in IIM by 
Reeves and colleagues in 1986 [227]. SRP is a cytoplasmic protein with a role in the 
recognition and translocation of newly synthesized proteins across the ER. Anti-SRP 
autoantibodies are present in approximately 1% of JDM patients [228] and 5% of adult 
myositis patients and have been associated with acute onset severe necrotizing myopathy and 
with systemic features (such as dysphagia [229]) that may be refractory to standard 
immunomodulatory treatments [230]. Anti-SRP autoantibody-positive patients have a 
decreased likelihood of cutaneous involvement [231]. Muscle biopsies from anti-SRP 
autoantibody positive patients classically demonstrate muscle fiber necrosis with minimal 
inflammatory cell infiltrate [144, 230].  
Anti-Mi-2 autoantibodies 
The autoantigen target, Mi-2, is a nuclear helicase protein, that forms part of the nucleosome-
remodeling deacetylase complex, which plays a role in gene transcription [232]. Anti-Mi-2 
autoantibodies are found in 11–59% of adult DM patients [233, 234], as well as 4–10% of 
JDM patients [235]. In work similar to studies on Jo-1 expression in target tissues, Mi-2 has 
been shown to be overexpressed in myositis muscle compared with normal muscle and in 
particular is upregulated in human DM myofibers expressing markers of regeneration [236, 
237]. This autoantibody has been demonstrated to be a specific marker for DM [233] and 
have typical cutaneous DM lesions, including Gottron’s papules, heliotrope rash, cuticular 
overgrowth, and V-sign and shawl sign rashes. Patients who have the anti-Mi-2 
autoantibodies often have a more favourable prognosis, with milder muscle involvement 
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and a decreased risk of ILD and malignancy and show good response to therapy compared 
to other myositis subgroups [220, 238]. 
Anti-TIF1-γ autoantibodies 
These autoantibodies are found in 20–30% of adult DM as well as in JDM [239, 240]. They 
target nuclear transcription factors belonging to the human transcriptional intermediatory 
factor (TIF1) family, primarily TIF1-γ, but also TIF1-α and TIF1-β [241] .The TIF1 family is 
a subgroup of the tripartite motif (TRIM)-containing proteins. TIF1-γ is a nuclear protein 
involved in controlling DNA transcription. Anti-TIF1-γ autoantibody is significantly 
associated with aggressive skin lesions (diffuse photoerythema, verucca-like papules, scalp-
and facial psorasiform lesions and back rashes), both in adult and juvenile DM [242], 
whereas the established association with paraneoplastic DM is largely confined to adult 
patients, especially to older individuals (>50 years). Patients with both anti-TIF1-α 
autoantibodies and anti-TIF1-γ autoantibodies more frequently had a malignancy, compared 
to patients with anti-TIF1-γ autoantibodies alone [241]. Furthermore, patients with anti-TIF1-
γ autoantibodies have a reduced prevalence of Raynaud's phenomenon, arthritis, calcinosis 
and ILD than anti-TIF1-γ-negative patients [242]. However, pruritus was found to be 
positively associated. Interestingly, Ro52 (also known as TRIM21) belongs to the same TIF1 
family, and is an E3 ligase and it ubiquitinates IRF8 [243]. 
Anti-SAE autoantibodies 
Anti-SAE autoantibodies were originally described by Betteridge and colleagues in 11 DM 
patients (8%) in a European myositis cohort. Anti-SAE autoantibodies target small ubiquitin-
like modifier activating enzyme (SAE) 1 and 2, which are involved in the post-translational 
modification of numerous targets, including protein kinases and transcription factors [244]. In 
all of the anti-SAE autoantibody studies completed, there is an association with DM and 
cutaneous involvement. Furthermore, the skin manifestations usually develop months before 
the onset of muscle weakness [244, 245]. 
Anti-MDA5 autoantibodies  
Antibodies against MDA5 (originally termed “anti-CADM-140” antibodies) were first 
described in 2005 [246]. In studies performed, these DM-specific autoantibodies have been 
detected in 13–35% of adult and juvenile DM patients [246, 247]. MDA5 is a cytoplasmic 
RNA-specific helicase that recognizes single-stranded RNA viruses [248]. It belongs to a 
family of retinoic acid-inducible gene I-like receptors that function as cytoplasmic sensors of 
pathogen-associated molecular patterns within viral RNA. These proteins drive type I IFN 
production and anti-viral gene expression, thus mediating the intracellular immune response 
to control virus infection. It has also been shown that Ro52 autoantibodies (another IFN-
inducing autoantigen) are found in 30% of anti-MDA5 autoantibody positive patients. The 
initial studies showed that patients with these autoantibodies typically have absent or mild 
muscle disease, so called amyopathic DM, but are at increased risk for developing rapidly 
progressive ILD with poor prognosis [249, 250]. Characteristic mucocutaneous features are 
also frequently found in DM patients with this specificity. These consist of skin ulceration 
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and/or tender palmar papules [251]. They also noted that patients with anti-MDA5 
autoantibodies had a higher risk of experiencing oral pain/ulceration and arthritis/arthralgia. 
Anti-NXP-2 autoantibodies 
Anti-NXP-2 autoantibodies, originally called “anti-MJ” were first detected in approximately 
25% of juvenile myositis patients [252]. The target autoantigen was subsequently identified 
as nuclear matrix protein 2 (NXP-2) and has been reported in 1-17% of adult cohorts [29, 30]. 
This autoantibody specificity is associated with severe muscle weakness, polyarthritis, joint-
and muscle contractures, calcinosis and intestinal vasculitis in JDM [253]. Anti-NXP-2 
autoantibodies have also been found to be associated with an increased risk of cancer in adult 
males [30].  
Anti-HMGCR autoantibodies 
A new autoantibody directed toward the 200-kDa/100-kDa complex, associated with 
necrotizing myopathy was described in 2010 [2]. Studies identified the autoantigen target as 
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) (the pharmacologic target of 
statin medication). Patients with anti-HMGCR autoantibodies have been characterized by an 
increased risk of muscle weakness, elevated CPK levels and myopathic changes on EMG. 
This autoantibody has been associated with statin use, but studies have also demonstrated the 
presence of anti-HMGCR autoantibodies in statin-naïve patients, leading to the proposal that 
anti-HMGCR autoantibodies are a marker of IMNM as opposed to statin-induced myositis 
[254, 255]. Anti-HMGCR autoantibodies are found in 5-7 % of the myositis patients [2, 256]. 
Anti-FHL1 autoantibodies 
Anti-FHL1 autoantibodies have been detected in 25 % of IIM patients, while patients with 
RA, Sjögren’s syndrome, SLE, SSc, mixed connective tissue disease (MCTD) and muscular 
dystrophies were largely anti-FHL1 autoantibody negative [257]. Myositis patients with anti-
FHL1 autoantibodies often present with severe skeletal muscle involvement. Furthermore, 
patients with anti-FHL1 autoantibodies develop dysphagia more often than anti-FHL1 
autoantibody negative patients. The presence of these autoantibodies has been associated with 
distal muscle weakness and clinical muscle atrophy and vasculitis. The autoantibodies target 
a muscle-specific and novel autoantigen, FHL1, four-and-a-half LIM domain 1. 
Immunization of myositis-prone mice with the autoantigen, FHL1, worsened muscle 
weakness and increased mortality. The anti-FHL1 autoantibodies may be a potential 
prognostic biomarker for a subset of severe IIM.  
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1.1.9.2 Myositis-associated autoantibodies (MAAs) 
MAAs are found in approximately 20% of adult myositis patients along with other 
connective tissue diseases. Although, they are less specific for myositis, they are still an 
important diagnostic marker and can correlate with clinical features.  
Anti-Ro52 autoantibodies/Anti-Ro60 autoantibodies/Anti-La autoantibodies 
Anti-Ro autoantibodies are found in some autoimmune diseases such as Sjögren’s syndrome, 
SLE, SSc and IIM. Anti-Ro autoantibodies recognize two distinct antigens, with molecular 
weights of 52 kD (Ro52/TRIM21) and 60 kDa (Ro60), respectively. Autoantibodies to 
Ro60/Ro52 occur in 9–35% of adult myositis patients, approximately 6% of JDM patients 
and 14–25% of myositis overlap patients. Anti-La autoantibodies occur in 2–7% and 4–12% 
of myositis and myositis-overlap patients. Ro52, also denoted TRIM21, belongs to the TRIM 
family of proteins, and is an E3 ligase that functions in the process of ubiquitination that 
regulates cell death and signal transduction [258, 259]. Anti-Ro52 autoantibodies occur 
frequently together with anti-Jo-1 autoantibodies, with studies demonstrating the presence of 
anti-Ro52 autoantibodies in 56–72% of anti-Jo-1-positive patients. Patients with both anti-Jo-
1 and anti-Ro52 autoantibodies have an increased risk of mechanic’s hands and malignancy 
and a poorer outcome (more severe myositis and joint impairment) than patients with anti-Jo-
1 autoantibodies alone. [260]. Furthermore, patients with anti-Jo-1 and anti-Ro-52 
autoantibodies have a poorer prognosis concerning ILD than patients with anti-Jo-1 
autoantibodies alone. Therefore it is important to test anti-Ro52 alongside the MSAs. 
Anti-Ro52 autoantibodies have been demonstrated to have a pathogenic role in development 
of congenital heart block in mothers with these autoantibodies [261]. Overexpression of Ro52 
can lead to ubiquitination of IFN regulatory factor (IRF)-8, which is a transcription factor for 
macrophages, DCs and B cells, as well as a regulator of type I IFNs which could become 
activated [243]. 
Anti-Ro60 autoantibodies are strongly connected to patients with Sjögren’s syndrome and 
SLE and frequently co-occur with anti-Ro52 autoantibodies. The La-antigen also co-occurs 
with Ro52/Ro60 antigens. Anti-Ro60 autoantigens bind to cytoplasmic Y RNAs, which may 
have a role in mRNA stability and translation [262]. 
Anti-U1RNP autoantibodies 
These autoantibodies are only found in 3-8% of adult and juvenile myositis, but are more 
common in patients with overlap conditions (25-40%). These patients rarely have myositis at 
initial presentation and have been reported to respond favourably to steroid treatment, 
suggesting that anti-U1-RNP autoantibodies are a marker of good prognosis in myositis [228, 
263]. The U1-small nuclear ribonucleic proteins (snRNPs) are involved in pre-messenger 
RNA processing and collectively are composed of at least 11 polypeptides and five snRNP 
molecules. 
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Anti-PM/Scl autoantibodies 
One of the most commonly occurring MAAs is the anti-PM/Scl autoantibody, which targets 
the 75-kDa or 100-kDa subunits of the nucleolar exosome complex. These autoantibodies are 
reported to occur in 4–12% of patients [263]. Anti-PM/Scl autoantibodies have been 
identified in various CTDs [264], but are most commonly associated with PM and 
scleroderma overlap, with an increased risk of ILD, inflammatory joint disease, Raynaud's 
phenomenon and mechanic’s hands. Anti-PM/Scl autoantibodies were originally reported to 
be a marker of good prognostic outcome, however in a study of long-term outcome of anti-
PM/Scl patients with myositis, only 10% of the patients achieved remission and 20% had 
worsened clinical status [265]. 
Anti-Ku autoantibodies 
The target antigen of anti-Ku autoantibody is a heterodimer of 70 kDa and 80 kDa proteins 
that is thought to be an activation subunit of DNA-dependent protein kinase. The Ku antigen 
has key roles in various cellular processes, including DNA double-strand break repair. These 
antibodies can be seen in 1-3% of PM and DM patients and in 9–19% of myositis patients 
with overlap syndromes [263]. The inflammatory myopathy is usually mild in anti-Ku 
positive patients and responds to corticosteroid treatment, but the lung involvement (ILD) is 
severe and refractory to corticosteroids [266]. 
IBM 
Only 17–43% of IBM patients are routinely found to be autoantibody positive, with the 
majority of these cases involving MAAs as opposed to MSAs [267]. However a novel 
autoantibody was found to target the autoantigen, cytosolic 5'nucleotidase 1A (5cN1A), 
which is a protein involved in the hydrolysis of adenosine monophosphate, leading to 
physiological control of energy balance, metabolic regulation and cell replication [268]. This 
autoantibody has also been found in 20 % of patients with SLE and in 36 % of patients with 
Sjögren’s syndrome. The rarity of anti-5cN1A autoantibodies in PM and DM patients still 
makes this autoantibody a key marker for differentiating between myositis subtypes [269]. 
1.1.10 Endothelial progenitor cells 
Generally, in the adult human organism, new blood vessel formation can occur in 2 ways: by 
endothelial sprouting from preexisting endothelial cells/angioblasts (angiogenesis) or by 
peripheral recruitment of endothelial progenitor cells (EPCs) (vasculogenesis) [270]. EPCs, 
primarily described by Asahara et al in 1997, [271] represent a population of bone marrow-
derived, CD34 positive, VEGF receptor-2 (VEGFR-2 or kinase-insert domain receptor 
[KDR]) positive, CD133-positive cells [272] that have the ability to differentiate into ECs 
and thus, make a significant contribution to new blood vessel formation [273] and play an 
important role in endothelial repair [274]. Progenitor cells are defined by their clonogenic 
(ability to form a colony from a single cell) and proliferative potential. Total EPCs are 
typically 0.001% of total peripheral blood mononuclear cells (PBMCs). EPCs have been 
shown to be a surrogate marker of endothelial health, and a reduction in the number of these 
cells is associated with increased risk of cardiovascular disease [275-277]. Depletion of EPCs 
has been reported in some diseases with vascular complications, including diabetes and RA 
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[278, 279]. Moreover, depletion of EPCs has been shown to be caused by excessive serum 
levels of type I IFNs and this may be linked to endothelial dysfunction and increased 
cardiovascular risk in SLE [280]. EPCs have been extensively studied since 1997 and are 
considered as a potential marker for endothelial regeneration ability as mentioned above. On 
the other hand, circulating endothelial cells (CEC) were studied as biomarker for endothelial 
injury [281]. CECs are mature ECs sloughed off from the vessel walls [282]. Yet, in the 
literature, there is also a huge incoherency in regards to terminology and protocols used. This 
results in misleading conclusions on the role of so called EPCs, especially in the clinical field. 
The discrepancies are mainly due to strong phenotypic overlap between EPCs and circulating 
angiogenic cells (CACs), which are monocyte and macrophage progenitors. Likely both 
EPCs and CACs are important in generation of ECs. Furthermore, SLE patients have 
decreased amount of circulating EPCs/CACs and have a decreased capacity to differentiate 
into mature ECs, even during quiescent disease [184, 283]. Thus, patients with SLE have an 
impaired repair of the damaged endothelium, and one proposed mechanism could be through 
the effect of the type I IFNs. Type I IFN levels are increased in sera of SLE patients [284] 
and lupus cells appear to be more sensitive to the effects of the type I IFNs [98]. Also, an IFN 
signature in PBMCs of patients with severe SLE correlates with disease activity [285]. As the 
microvasculature is known to be affected in patients with myositis, particularly in patients 
with DM, with loss of capillaries in muscle tissue as a well recognized phenomenon, and with 
the more recent observations of activation of the type I IFN system in patients with myositis, 
we wanted to further investigate if the phenotype and function of EPCs is altered also in 
myositis and if so, if there is an association to the type I IFNs. Therefore, we initiated a study 
which resulted in paper IV. 
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2 AIMS 
The overall aim of my thesis was to get an increased understanding of molecular mechanisms 
that are involved in IIM with a focus on the type I IFN system, autoantibodies and 
mechanisms that may induce immune reactivity, to be able to subclassify patients. 
The specific aims were: 
• To assess the diagnostic accuracy of a novel and commercially available line blot 
assay with myositis-related autoantibodies and to validate the test results against those 
obtained using established autoantibody detection techniques (Paper I). 
• To investigate if smoking is a risk factor for development of subgroups of PM/DM, in 
particular, a subset with anti-Jo-1 autoantibodies and a certain HLA-type (Paper II). 
• To investigate whether autoantibody profiles in myositis are associated with 
activation of the type I IFN system and whether there is a correlation with disease 
activity, clinical manifestations, or HLA haplotype (Paper III). 
• To investigate whether type I IFN and IL-18 is linked to EPC depletion, activation 
and dysfunction in IIM patients (Paper IV). 
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3 PATIENTS  
Patients included in the thesis were recruited from the Rheumatology Clinic, Karolinska 
University Hospital, Stockholm, Sweden, the University of Padova, Padova, Italy, the VU 
University medical center, Amsterdam, the Netherlands, the Institute of Rheumatology, 
Prague, Czech Republic, the outpatient Rheumatology Clinic, University of Michigan, Ann 
Arbor, Michigan, USA, University of Manchester, Salford, United Kingdom (UK) and from 
the University of Debrecen, Debrecen, Hungary. Patients were diagnosed with definite or 
probable PM/DM according to Bohan and Peter’s criteria [6, 7] and patients with IBM were 
diagnosed according to Grigg’s criteria [9]. All patients and controls gave their written 
informed consent to participate in the studies. 
Several different groups of patients were included. 
3.1 PAPER I 
208 patients [PM (n=100), DM (n=63), JDM (n=2), overlap (n=27), cancer-associated 
myositis (CAM)(n=9), ASS (n=7)] were included in this study. 137 patients from the 
Division of Rheumatology, University of Padova, Padova, Italy, between January 1999 and 
May 2008, and 71 patients from the Rheumatology Unit of Karolinska University Hospital, 
Stockholm, Sweden, within the above mentioned period, were enrolled. Overlap myositis was 
defined when the patient satisfied one or more classification criteria of at least one CTD in 
addition to the myositis diagnosis. 50 age-and sex-matched HCs or 180 patients with various 
diseases including 11 non-autoimmune myopathies, 23 sporadic or genetic muscular 
dystrophies, 11 CTDs, 68 SLE, 36 SSc, 22 primary Sjögren’s syndrome and 9 arthropathies, 
where tested as healthy or disease controls. The patients’ clinical characteristics are presented 
in table 4. 
3.2 PAPER II 
A cohort of 557 patients with PM (n=276), DM (n=213) or overlap (n=68) from the 
rheumatology units in Hungary, UK, Sweden and the Czech Republic were included in this 
study. The inclusion criteria were PM, DM or myositis-overlap with concurrent information 
about HLA-DRB1 genotype, smoking history and anti-Jo-1 autoantibody status. Patients with 
myositis-CTD overlap either had their primary disease with probable or definite myositis 
according to Bohan and Peter’s criteria [6, 7] or had possible myositis but additionally had a 
confirmed MSA or MAA. The patients’ clinical characteristics are presented in table 4. 
3.3 PAPER III 
A cohort of one hundred and eight patients with PM (n=40), DM (n=46) and IBM (n=6) who 
fulfilled the criteria for definite or probable PM/DM [6, 7] or possible IBM [9] were included 
in this study. The patients were enrolled between 2006-2009 from the Rheumatology Unit, 
Karolinska University Hospital, Stockholm, Sweden and from the Institute of Rheumatology, 
Prague, Czech Republic. Twenty-nine patients of these were Czech and 79 patients were 
Swedish. Exclusion criteria were treatment with a biological agent, presence of overlap 
syndrome or no available antinuclear antibody (ANA) status. Twelve of the Swedish patients 
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were excluded according to the exclusion criteria and four patients due to missing IFN data 
due to technical issues. The remaining 92 were included. Ten of the Swedish patients and 2 of 
the Czech patients were newly diagnosed and had at time of blood sampling no medication. 
Forty-seven patients with SLE were recruited at the Rheumatology department, VU 
University medical center, Amsterdam, The Netherlands, as a comparator group. Forty-one 
healthy controls (HCs) (23 female and 18 male; mean age 35 years) were recruited at the VU 
University Medical Center, Amsterdam, the Netherlands. The patients’ clinical characteristics 
are presented in table 4. 
3.4 PAPER IV 
Two cohorts (cohort 1 and 2) were included in this study. Thirty-six patients with PM (n=24) 
or DM (n=12) from the well-characterized myositis cohort at Karolinska University Hospital, 
Stockholm, Sweden were included in cohort 1. Twenty-five patients with PM (n=17) or DM 
(n=8) were recruited between 2010-2012 at the outpatient Rheumatology Clinic, University 
of Michigan, Ann Arbor, USA (cohort 2). Exclusion criteria were IBM, current or recent 
infections (within 1 week), pregnancy or cancer. Matched HCs were recruited by 
advertisement at the University of Michigan. The patients’ baseline characteristics are 
presented in table 4. 
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Table 4. Patient characteristics at baseline 
Characteristics* Paper I Paper II Paper III               Paper IV             
Cohort 1        Cohort 2 
Diagnosis, n (%) 208 557 92 36 25 
   PM 100 (48) 276 (50) 40 (43) 24 (67)  17 (68) 
   DM 65° (31) 213  (38) 46 (50) 12 (33) 8 (32) 
   IBM 0 0 6 (7) 0 0 
   MCTD 0 0 0 0 0 
   Overlap/CAM/ 
   ASS 
27 (13)/ 
9 (5)/7 (3) 
68 (12)/0/0 0 0 0 
Sex, n (%)      
    Men/women 49 (24)/ 
159 (76) 
139 (25)/ 
418 (75) 
30 (33)/ 
62 (67) 
10 (28)/ 
26 (72) 
11 (44)/ 
14 (56) 
Age, years n/a 48 (37- 58) 58 (49-68) 60 (48-69) 57 (33-68) 
Disease 
duration,years 
1 (0-31) 
(mean+SD) 
n/a 3.0 (0.3-
9.6) 
2.2 (0.1-
6.7) 
n/a 
Physician’s global 
disease activity 
assessment,mm 
n/a n/a 7 (0-23) 13 (3-40) n/a 
Patient’s global 
disease activity 
assessement,mm 
n/a n/a 36 (16-64) 46 (24-63) n/a 
MMT8, (0-80) n/a n/a 91 (72-99) 75 (68-79) n/a 
HAQ (0.00-3.00) n/a n/a 0.50 (0.00-
1.25) 
0.94 (0.40-
1.50) 
n/a 
CPK, µkat/liter n/a n/a 2.00 (1.05-
8.23) 
3.00 (1.10-
12.38) 
n/a 
AST, µkat/liter n/a n/a 0.50 (0.39-
0.73) 
0.53 (0.35-
0.97) 
n/a 
ALT, µkat/liter n/a n/a 0.53 (0.35-
1.05) 
0.41 (0.27-
0.90) 
n/a 
LDH, µkat/liter n/a n/a 3.60 (3.08-
4.42) 
5.60 (3.42-
7.58) 
n/a 
Extramuscular 
global assessment, 
mm 
n/a n/a 5 (0-14) 12 (0-29) n/a 
Immunomodulatory 
drugs, n (%) 
n/a n/a 55 (60) 18 (50) 21 (84) 
Daily dose of 
Prednisolone, mg 
n/a n/a 10 (4-18) 4 (0-10) 8 (5-50) 
Antibody profile†, n           
Jo-1 s 115 (21) 23 14 8 
PL7 e n/a 1 1 2 
EJ e n/a 0 0 1 
Ku  n/a 1 1 0 
Ro52/Ro60 r n/a 22/9 6/0 3/0 
Mi-2 e n/a 0 3 1 
PM/Scl 75/100 s n/a 7 0 0 
SRP u n/a 2 1 0 
U1RNP l n/a 8 3 3 
La t n/a 4 1 1 
TIF1 gamma s n/a 0 2 0 !
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*All data are from time of blood sampling and presented as median (IQR; interquartile range) if not stated otherwise. PM, Polymyositis; DM, 
Dermatomyositis; MCTD, Mixed Connective Tissue Disorder; Disease duration, years from diagnosis till sampling date; Physician’s global 
disease activity assessment (Visual Analogue Scale (VAS), from 0-100 mm,) Patient’s global disease activity assessment (VAS from 0-100 
mm); Extramuscular global assessment (VAS from 0-100 mm); MMT8, Manual muscle test (0-80); HAQ, Health Assessment Questionnaire 
(potential score 0.00-3.00); CPK, creatine phosphokinase (normal levels: 0.6-3.5 µkat/liter); AST, Aspartate aminotransferase (normal levels 
<0.61 µkat/liter); ALT, Alanine aminotransferase (normal levels <0.76 µkat/liter); LDH, lactate dehydrogenase (normal levels <3.5 
µkat/liter); Immunomodulatory drugs includes cyclophosphamide, methotrexate, azathioprine, cyclosporin A, and intravenous 
immunoglobulin; (n/a), not assessed. CAM, Cancer-associated myositis; ASS, Antisyntethase syndrome with subclinical myositis. One 
patient could have several autoantibody specificities. ° two of these patients have the diagnosis juvenile DM 
 
4 METHODS  
4.1 GENOTYPING  
HLA-typing was performed for all the myositis patients in paper II, in order to examine 
whether smoking was associated with development of anti-Jo-1 autoantibodies in HLA-
DRB1*03 positive IIM. HLA-typing was also done for all patients in paper III, in order to 
investigate a possible link between HLA type and IFN activity, by sequence-specific primers 
PCR [286] in CMM Research Laboratory, Stockholm, Sweden (Swedish patients) and in the 
Institute of Rheumatology, Prague, Czech Republic (Czech patients). 
In the paper II and III, primers were designed for DR “low –resolution” typing by sequence-
specific primers PCR i.e. identifying polymorphisms corresponding to the serologically 
defined series DR1-DRw18. 
Sequence-specific primers PCR is an accurate typing technique with high sensitivity, 
specificity and reproducibility. The method is rapid (two hours) and inexpensive, and is 
suited for analyzing small numbers of samples simultaneously. The method contains DNA 
preparation, PCR amplification, post-amplification processing, gel detection, documentation 
and interpretation. 
4.2 AUTOANTIBODY ANALYSES 
Autoantibodies are important for the evaluation of patients with systemic autoimmune 
diseases. This is because of their inclusion in diagnostic and classification criteria, their 
correlation to certain clinical manifestations and their association to disease activity. Assays 
to detect autoantibodies should therefore be reproducible, reliable, easy to perform and 
available in everyday clinical practice. 
In paper I line blot assay was validated to standard immunoprecipitation (IPP) and 
immunoblot. In paper II, only line blot assay was used and in paper III both line blot assay 
and IPP were used to detect autoantibodies. In paper IV, line blot assay and IPP (cohort 1) 
and a multiplex assay (cohort 2) were used. In papers III and IV, patients were defined as 
positive for an autoantibody if the autoantibody status was positive in one of the two used 
methods. Multispecific autoantibody status was defined as presence of two or more 
autoantibodies, antinuclear antibody (ANA) not included. 
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4.2.1 Line blot assay 
This test is based on the principal of line immunoassay in which recombinant antigens, 
synthetic peptides or natural antigens are coated as discrete, parallel lines on a membrane. 
These strips are incubated sequentially with diluted patient sample, horseradish peroxidase 
labeled secondary antibody and a substrate. Readings are made by comparing the intensity of 
the reaction with control lines. The strip is coated with multi-antigens which allows for 
simultaneous detection of different autoantibodies using small serum volumes and make it 
possible to discriminate between unspecific background signal and real reaction with the 
present antigen. It is also a semi-quantitative method, since each autoantibody can be 
quantified and divided into a low or high titer. A similar method is the immunoblot (Western 
blot), where the separation of the proteins are made with gelelectrophoresis by molecular 
weight. Thereafter the proteins are transferred (blotted) to a membrane (nitrocellulose or 
nylon) and identification of the protein is made by incubation of the patient sample and a 
labeled secondary antibody and substrate as mentioned above. 
4.2.2 Immunoprecipitation 
IPP is a technique of precipitating a protein antigen out of a solution using an antibody that 
specifically binds to that particular protein. This process can be used to isolate and 
concentrate a non-abundant protein from a sample containing many thousands of different 
proteins, such as a whole cell extract. IPP requires that the antibody is coupled to a solid 
substrate at some point in the procedure, with assays generally immobilizing antibodies using 
superparamagnetic microbeads or microscopic agarose (non-magnetic) beads. For 
radiolabeled IPP, a S35 methionine labelled protein mixture is added to the bead-autoantibody 
complex and proteins targeted by the autoantibodies are immunoprecipitated and captured 
onto the beads. After heating, proteins are fractionated by gel electrophoresis, enhanced, fixed 
and dried. Labeled proteins are analyzed by autoradiography (X-ray film). IPP has been 
regarded as the gold standard testing method for autoantibody serology due to its high 
sensitivity and ability to detect a wide repertoire of known and unknown autoantigen targets 
[287]. However, the test requires a specialist centre and is both time-consuming and labour-
intensive. IPP also has the disadvantage of not being able to distinguish between 
autoantibodies targeting proteins of the same molecular weight and it is a non-quantitative 
assay [288]. 
4.2.3 Multiplex assay (Bioplex 2200) 
In paper IV, cohort 2, serum samples were screened for autoantibodies with the Bioplex 2200 
assay. This method is an immunoassay, which uses very small magnetic beads, each coated 
with a different autoantigen. The bead sets are then incubated with the patient sera, containing 
the autoantibodies. A secondary antihuman-IgG antibody conjugated to a fluorophore is 
added to detect the autoantibodies bound to the antigen-coated beads. A dual-laser detects the 
individual bead results for each assay. The multiplex assay is a quantitative, fully automated 
assay, requiring no user input after the initial loading of primary tubes. The system can 
automatically process up to 100 samples per hour. First results are available in 40-60 minutes. 
This assay still needs to be fully validated [289]. 
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4.2.4 Immunofluorescent assay 
This assay is one of the most commonly used methods for testing autoantibodies. In papers 
III and IV, ANA was screened by an immunofluorescent assay, which is the gold standard 
method for ANA screening. This is a method in which a patient’s blood sample is mixed with 
Hep-2 cells that are affixed to a slide, enabling autoantibodies that exist in the blood to react 
with the cells. The slide is treated with a fluorescent tagged secondary antibody reagent and 
examined under a fluorescent microscope. The presence or absence and pattern of 
fluorescence is noted. This method is labor intensive, but an excellent screening test in expert 
hands, who know how to process and read the slides. Furthermore, in the case of myositis 
autoantibodies, the results are often negative or nonspecific, as many of the MSAs are 
cytoplasmic. In some laboratories this method has been replaced by multiplex methods (see 
chapter 4.2.3). 
4.3 IFN ASSAYS 
In this thesis we have had collaboration with colleagues in the USA and in Europe, and the 
IFN assays used have been decided depending on what IFN assay is mostly used in the 
different laboratories that we collaborated with. 
There are four main types of assays used to measure IFNα/β production. ELISAs and 
bioassays can be used to measure secreted IFNα and IFNβ. Polymerase chain reaction (PCR) 
is commonly used to detect IFNα and IFNβ mRNA expression by pure cell populations. 
Intracellular cytokine staining protocols detect IFNα/β production by flow cytometry. 
Measuring circulating IFN-α in serum is less sensitive compared to measuring type I IFN-
inducible genes, as has been reported in many studies [200, 290-292].  The bioassay is the 
most sensitive assay, followed by ELISA and then the intracellular staining protocol [293]. 
These assays have different advantages and disadvantages. Detection of mRNA levels by 
PCR will not identify the IFN-producing cell unless a pure cell population is used and the 
results may not reflect protein production. However, several subtypes of IFNα production can 
be assayed simultaneously. ELISAs allow unambiguous detection of secreted protein. The 
IFN bioassays are more complex experiments, take longer time (5-6 days), but use less 
expensive reagents and equipment and detect production of functional IFN proteins using a 
relevant bioassay system. Intracellular staining protocol is a quick method (3-4 hours) for 
detecting the production of specific types of IFN protein by identified cell types within mixed 
cell population. 
4.3.1 IFN signature in whole blood 
This method was used in paper III. For whole blood RNA isolation, 2.5 ml blood was drawn 
in PAXgene tubes and RNA isolation, quantification and purification was performed as 
previously described [294]. RNA was reversely transcribed into cDNA by using a cDNA 
synthesis kit. Real-time PCR analysis was performed. Relative quantities were calculated 
using the ddCT method. GAPDH was used as a housekeeping gene and all arrays contained 
two samples for calibration.  
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The average expression of eight IFN-regulated genes (IRG), IFI3, IFIT2, MxA, IFI44L, 
HERC5, IFIT1, RSAD2 and OAS3, (all corrected versus GAPDH, log2 according to earlier 
studies) was used as the IFN score [193, 214]). Since the IRGs were highly correlative, we 
calculated an IFN score by averaging the expression levels of all IRGs per sample [295-297].  
The mean + 2 standard deviation (SD) of the IFN score in HC (n=41) was used as a cut off to 
define if an IFN signature was present (IFN-score > 4.84=IFN high) or absent (IFN-score 
<4.84=IFN low). 
4.3.2 IRG induction assay and neutralization 
The IRG induction assay was used in paper III, to test if patient sera had the property to 
activate the type I IFN pathway. Briefly, healthy PBMCs were incubated with 20% patient 
serum from 20 randomly selected patients with IIM for 4 hours or 8 hours at 37°C and 5 % 
CO2. Next, to identify the specificity of type I IFN, 25 randomly selected samples from 
patients with IIM were co-cultured with neutralizing anti-IFNα antibody or neutralizing anti-
IFNα-receptor (IFNAR2) antibody. After incubation, cells were harvested, washed and lysed 
in both experiments. RNA isolation from cells and reverse transcription of cDNA and real 
time quantitative (q)PCR was performed and assessed (see chapter 4.3.1) with the exception 
that the expression levels of target genes were calculated relative to housekeeping gene 18S 
ribosomal RNA (18SrRNA). To correct for any variations between experiments, all expression 
values are relative to healthy controls. The overall IRG induction was determined by 
calculating the average expression of three known IRGs; RSAD2, IFI44L and MX1 [295, 
296]. The average ex-vivo whole blood IRG induction for all samples (1.96) was used to 
subdivide patients into IFN high and IFN low. 
4.3.3 Type I IFN serum activity 
In paper IV, sera from 36 IIM patients recruited from Karolinska University Hospital were 
analyzed for their IFN-inducing ability using a validated bioassay [200] employing cell 
cultures [283]. This bioassay measures the functional effects of serum on the gene expression 
of cultured target cells, an epithelial cell line (HeLa cells). The induction of three type I IFN-
inducible genes IFI44, IFIT1 and PRKR was quantified by real-time qPCR. Samples were 
normalized to media alone after normalization to house-keeping gene HPRT-1 and fold 
change (FC) was calculated as compared to samples exposed to serum from healthy controls.	  	  
The	   IFN score was calculated as previously reported [290]: [myositis patientsFC-meanFC of 
healthy controls (HC)]/standard deviation HC) and was calculated for each gene followed by 
summation of all three gene scores to generate the composite index.   
4.4 ELISA  
ELISA is commonly used for detection of proteins and autoantibodies in fluid, such as sera or 
plasma. ELISA is a quick method and produces quantitative data, but the drawback is the 
dependence on a standard curve.  
In paper IV we used a human quantitative ELISA for detection of IL-18. The ELISA plates 
are precoated with an anti-human IL-18 antibody onto microwells. Human IL-18 present in 
the sample binds to the IL-18 antibodies in the microwells. An enzyme-labelled (e.g. biotin) 
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secondary antibody binds to human IL-18 captured by the first antibody. This is followed by 
the substrate-chromogen which forms a colored reaction product that is visible, in proportion 
to the amount soluble human IL-18 present in the sample. A standard curve is prepared from 
7 human IL-18 standard dilutions and human IL-18 sample concentration determined.  
4.5 ASSAYS FOR EPC DIFFERENTIATION AND QUANTIFICATION 
Currently, it is accepted standard to measure the circulating numbers of EPCs by flow 
cytometry using either antibodies against CD34 and KDR or CD133, whereas the functional, 
clonogenic capacity should be evaluated using colony-forming unit assays [276] or 
monolayer formation. ECs initially form colonies (around day 7) from which mature ECs 
then migrate and form a monolayer (between day 14-21).  Ideally, cells are stained with 
markers to prove they are mature ECs, but morphology (monolayer formation) is another way 
to judge. Monolayer formation is one way to measure endothelial cell differentiation. In paper 
IV we wanted to study the differentiation into ECs, and not just early EPC function, therefore 
we studied the monolayer formation.   
4.5.1 Flow cytometry 
Flow cytometry provides rapid characterstics of single cells. The information obtained is both 
quantitative (cell counting) and qualitative (cell size, internal complexity, that is cell sorting). 
The basic principle of flow cytometry is the passage of cells in single file in front of a laser, 
in a flow cytometer, so they can be detected, counted and sorted. Cell components are 
fluorescently labeled and then excited by the laser to emit light at varying wavelengths. The 
fluorescence can then be measured to determine the amount and type of cells present in a 
sample. 
In paper IV circulating EPCs were characterized and quantified by flowcytometry in patients 
of cohort 2 and in matched controls. 
4.5.2 In vitro differentiation into mature endothelial cells 
PBMC differentiation into EC-like cells is an accepted method to assess the functionality of 
EPCs [279, 283, 298], that we used in paper IV. Briefly, PBMCs were cultured in EC-
specific enrichment medium on fibronectin-coated wells. Media was changed 120 hours after 
plating, then every 2 days. Typically in 2-3 weeks, these cells differentiate into ECs by 
forming a monolayer. Wells that had monolayer formation (detected by light microscopy) 
were scored as EC-monolayer forming or not-EC-monolayer forming. This method 
(monolayer formation) was used in cohort 2 in paper IV. This is a quick way of evaluating if 
there has been a differentiation from EPCs to ECs. Staining with acetylated-LDL (ac-LDL) 
and UEA-1, followed by fluorescent microscopy, is a confirmation of this assay as it detects 
specific EC markers (see 4.5.3). This is labor intensive, but more specific than monolayer 
formation. If cells are stained with ac-LDL and UEA-1, then we can be sure that a monolayer 
has been formed.   
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Figure 6. Myositis sera inhibits EPC differentiation in vitro. Representative fluorescent photomicrograph 
examining staining of ac-LDL (red) and UEA-1 (green) in EC cultures at day 14 with and without type I IFN 
receptor blockade (IFNR) or IL-18 neutralization. The overlap yellow staining represents cells that are double 
positive and most likely a mature EC. Jo-26 represents sera from a representative myositis patient. The 
photomicrograph is published courtesy of Dr Michelle Kahlenberg. 
4.5.3 Blocking experiments 
In cohort 1 in paper IV, we wanted to assess the effect of PM and DM serum on EPC 
differentiation into mature ECs. We therefore proceeded to isolate healthy control EPC-
containing PBMCs and cultured them in proangiogenic conditions as above (see chapter 
4.5.2), in the presence or absence of 30 % healthy control or PM/DM serum from cohort 1, 
for the first three days of culture. EC differentiation was assessed as above (see chapter 
4.5.2). On day 14 of culture, by incubation with markers of mature ECs (ac-LDL and 
fluorescein labeled UEA-1), followed by live cell fluorescent microscopy, images were 
acquired at room temperature at 100X total magnification (figure 6). Three random fields of 
view were acquired per every triplicate well. The data was presented as one combined mean. 
Cells that co-expressed ac-LDL and UEA-1 were quantified as ECs. In some experiments, 
neutralizing antibodies to IL-18 or the type I IFN receptor or isotype control were added 30 
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min prior to addition of human serum. We could then study if neutralizing antibodies to IL-18 
or antibodies to the type I IFN receptor affected the EPC differentiation into  mature ECs. 
4.6 TAQMAN PCR 
 TaqMan reverse transcription qPCR (TaqMan qPCR) is one of two types of quantitative 
PCR methods. Unlike the other type of quantitative PCR which uses a fluorescent dye that 
can bind any double-stranded DNA, Taqman qPCR uses a fluorogenic probe, which is a 
single stranded oligonucleotide of 20-26 nucleotides and is designed to bind only the DNA 
sequence between the two PCR primers. So only specific PCR products can generate 
fluourescent signals in TaqMan qPCR. This method allows a sensitive, specific and 
reproducible sequence detection down to single nucleotide resolution. Expression of IFN-
regulated genes involved in IFN production in paper III and IV, was assessed using TaqMan 
qPCR following RNA extraction and cDNA synthesis. 
4.7 STATISTICAL ANALYSES 
In paper I differences in frequencies of dichotomous variables were analyzed by chi-squared 
test or Fisher’s exact test, when appropriate. P-values below 0.05 were considered statistically 
significant. Concordance between methods was evaluated by contingency tables. Diagnostic 
accuracy for IIM was measured by sensitivity, specificity, positive and negative predictive 
values for any antibody specificity investigated. Sensitivity (%) for IIM = (number of 
MSA/MAA positive patients with IIM/total patients with IIM) x 100. Specificity for IIM 
(with respect to healthy subjects) = (number of MSA/MAA negative healthy subjects/total 
healthy subjects) x 100. Specificity for IIM (with respect to disease controls) = (number of 
MSA/MAA negative disease controls/ total disease controls) x 100. Data were statistically 
analysed using SPSS 15.0I statistical package (Windows version) 
In paper II, individual associations were derived from 2x2 contingency tables using the chi-
squared test, or two-tailed Fisher’s exact test when individual cells valued five or less. Data 
were expressed as odds ratio (OR) with exact 95 % confidence interval (CI). Pointwise p-
values were not corrected as the association with HLA-DRB1*03 and IIM is well established 
in the literature [299, 300]. The described analyses were also repeated after stratification by 
smoking and anti-Jo1-status using multinominal logistic regression. Data were analysed by 
the statistical package Stata (release 9.2). 
In paper III, the significance of differences between groups was calculated by Mann-
Whitney U-test or Student’s t-test when appropriate for continuous variables, or by Pearson’s 
chi square tests or Fischer’s exact test for categorical variables. Differences in IRG induction 
over time were tested using a paired t-test. Correlation analyses were done using Pearson r or 
Spearman r tests. P-values <0.05 were considered statistically significant. Data were analyzed 
using GraphPad Prism 4 or 5 Software.  
In paper IV, the significance of differences between groups was calculated by Mann-
Whitney U-test. Correlation analyses were done using linear regression analysis. Comparison 
of improvement with IL-18 or type I IFN receptor blockade was performed using paired, 2-
sided Student’s t-test. Difference between the means in the EPC quantification and 
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monolayer assay was analyzed using an unpaired Student’s t-test. P-values <0.05 were 
considered statistically significant. All analyses were done using GraphPad Prism 6 Software. 
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5 RESULTS AND DISCUSSION 
In the following sections the main results of paper 1-IV are summarized and together with 
unpublished data, discussed in the context of recent findings and literature. 
5.1 PAPER I  
Serological testing for MSAs and MAAs is useful for the diagnosis, prognosis and treatment 
response of IIMs. However, available assays need to be standardized and validated. The 
objective of this paper was to evaluate the accuracy of a novel commercial line blot assay 
compared to established autoantibody detection methods (IPP and immunoblot). 
We found that with the line blot assay, any MSA or MAA was detected in 98/208 (47%) of 
the myositis patients, in 2/50 (4%) of the healthy subjects and in 70/180 (39%) of disease 
controls. Regarding IPP/immunoblot, any MSA or MAA was detected in 106/208 (51%) of 
the myositis patients, in 3/50 (6%) of the healthy subjects and 47/180 (26%) of the disease 
controls.  
The diagnostic specificity of line blot with respect to healthy/disease controls was 100% for 
anti-Jo-1, anti-PL-7 or PL-12, anti-PM/Scl; 96% for anti-Ku, 98% for anti-Mi-2 and 76% for 
anti-Ro52. Notably, anti-Ku and anti-Mi-2 false positive cases were mainly found in SLE 
patients.  
The diagnostic specificity of IPP/immunoblot with respect to healthy/disease controls was 
100% for anti-Jo-1, anti-Mi-2, anti-PM/Scl, 97% for anti-ARS non Jo-1 (94% towards 
healthy subjects and non-immune myopathies, and 98% towards CTD patients), 98% for anti-
Ku (100% vs. healthy subjects and non-immune myopathies, and 99% vs. CTD patients), 
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82% for anti-Ro52 (100% vs healthy subjects, 94% vs non-immune myopathies and 73% vs 
CTD patients). 
In summary, IPP/immunoblot confirmed the line blot assay results as regard to anti-Jo-1, anti-
PM/Scl and anti-Ku positivities, but IPP/immunoblot was somewhat more sensitive than line 
blot in detecting anti-Mi-2 and anti-ARS non-Jo-1 autoantibodies in patients with IIM.  
The sensitivity of the anti-Mi-2 autoantibody was lower when it was detected by line blot 
assay than by immunoblot. This could depend on the nature of the antigen, since the Mi-2 
autoantigen is composed of at least two isoforms, Mi-2α and Mi-2β. In this version of the 
line blot assay only Mi-2β was detected, in contrast to in immunoblot. Improvement of the 
sensitivity has been made in the new version of line blot strips, where both the Mi-2α and 
Mi-2β epitopes can be detected. Furthermore, the sensitivity of anti-ARS non-Jo-1 
autoantibodies was lower when these autoantibodies were detected by line blot than by IPP. 
This can partly be due to the limited number of anti-ARS specificities detectable at that time 
in the line blot assay (i.e. PL-7, PL-12), contrary to IPP where any anti-ARS autoantibody 
can be detected. 
Another limitation in this paper was that the healthy and disease controls were from Italy, but 
the patients were from both Italy and Sweden. However, there was no difference in clinical 
characteristic or antibody profile between the Italian and the Swedish cohort, apart from a 
lower relative prevalence of the anti-Mi-2 autoantibody and DM in the Swedish patients. This 
is likely due to differences in environmental factors or HLA profiles between the two 
populations. One known environmental factor that is different in Sweden compared to Italy is 
the degree of UV-light radiation. As it has been reported previously, that UV-light exposure 
increases risk to develop both Mi-2 autoantibodies and clinical features of DM this is a 
plausible explanation for the observed difference in our two-center study, but influence of 
other environmental or genetic factors cannot be excluded. 
We could confirm that the anti-Ro52 autoantibody is not specific for IIM by means of either 
line blot or IPP/immunoblot and this reduces the accuracy of both tests to be used as 
diagnostic tests. By excluding the anti-Ro52 autoantibody detection both methods achieved a 
specificity higher than 90% but without losing sensitivity (40%). However, anti-Ro52 
autoantibodies are often present in combination with one MSA such as anti-Jo-1 
autoantibodies, and it has an additional value to detect anti-Ro52 autoantibodies as they may 
confer a worse prognosis when present together with an MSA [260].  
In our study, the line blot assay available at that time, detected seven myositis antigens, but 
nowadays 16 myositis antigens (Mi-2α, Mi-2β, TIF1-γ, MDA5, NXP-2, SAE-1, Ku, 
PM/Scl100, PM/Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro52) can be detected by this assay. 
We nowadays have the possibility to test sera from myositis patients in the department of 
Clinical Immunology, Uppsala Akademiska Hospital, Sweden, where the novel line blot 
assay is used and analyses are performed several times per week.  
The line blot assay is not only a qualitative method, it can also be used as a semi-quantitative 
method, since each autoantibody can be quantified and divided into low or high titer. 
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Furthermore, the line blot assay is fast and reproducible, and is easy to perform and can 
therefore be used in routine clinical laboratories. 
In conclusion, we found that the line blot test is an accurate serological test. Positive MSAs, 
more than MAAs, support the diagnosis of myositis and with a high likelihood rule out other 
systemic rheumatic diseases or myopathies, thus representing a reliable alternative to the 
more time-consuming and complex IPP and immunoblot and feasible to use in clinical 
routine testing. For research projects where we want to test many sera or if we want to search 
for new autoantibody specificities we suggest an algorithm to first screen with the line blot 
assay and if patients are “seronegative” by the line blot assay, they can then proceed to the 
“gold standard” IPP and/or immunoblot. 
5.2 PAPER II 
The aim of this study was to examine whether smoking was associated with anti-Jo-1 
autoantibodies in HLA-DRB1*03-positive IIM. 
Interestingly, the frequency of smoking was higher in anti-Jo-1 autoantibody positive 
myositis patients across all four cohorts, compared to anti-Jo-1 autoantibody negative 
patients. In a cohort of 557 patients from four European centers, we found that the frequency 
of anti-Jo-1 autoantibodies was 21%. The frequency of anti-Jo-1 autoantibodies when 
compared between countries was broadly similar, although the highest frequency was noted 
in the Czech cohort, and the lowest in the Swedish cohort. We defined a patient as “ever 
smoker” if a patient stated that they had ever smoked as much as one cigarette a day for as 
long as a year. The overall frequency of “ever smoking” was 39% and a difference was noted 
between the countries. The lowest frequency was noted in the Hungarian cohort, the highest 
in the UK cohort. The overall frequency of  “ever smoking” 39%, is a high value. 
Furthermore, in the Swedish cohort 54 % were ever smokers, and the current smoking 
prevalence in the overall population in Sweden is about 21% (men 23%, women 20%, 16-84 
years old) (WHO, www.who.int.). There is no universal definition of a smoker, and therefore 
the smoking prevalence varies from study to study and within countries and between 
countries. One explanation for the variations in frequency of smoking between the countries 
could possibly be due to variations in methods on how the information on smoking habits 
was retrieved. Patients in our study cohort, from the other three countries received a 
questionnaire where the smoking question could be answered. However, for the Swedish 
cohort the patients were interviewed over the phone. It could be so, that it is easier to capture 
smoking habits during a telephone call than by paper, explaining the higher smoking 
frequency in the Swedish cohort. Hungary had the lowest frequency 22%, which is in line 
with reported smoking prevalence in the overall Hungarian population (WHO, 
www.who.int.). Perhaps differences in tendency to admit smoking habits also contributes to 
the reported different smoking frequencies between the countries. 
As has been previously described, we found a strong association between HLA-DRB1*03 and 
anti-Jo-1 status across all four cohorts combined [92, 93]. Furthermore, the frequency of 
HLA-DRB1*03 was higher in smokers than in non-smokers, and this association again 
reached statistical significance in the Hungarian cohort, like the association between smoking 
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and anti-Jo-1 autoantibody positivity also reached statistical significance in the Hungarian 
cohort. Our results suggest that there is an additional risk to develop anti-Jo-1 autoantibodies 
in HLA-DRB1*03-positive ever smokers. 
In conclusion, this study has shown that smoking is associated with IIM patients who are 
either anti-Jo-1 autoantibody and/or HLA-DRB1*03 positive. The association of the presence 
of anti-Jo-1 antibodies is further increased in IIM patients who are both smokers and possess 
one or more copies of HLA-DRB1*03. It would be interesting to further subgroup the 
smokers with the help of an environmental questionnaire, in regards to, how many cigarettes 
were smoked per day, the duration of smoking in years, the cumulative dose of cigarette 
smoking (in some studies referred to as pack-years) and when cessation of smoking was in 
relationship to clinical disease onset. Furthermore, it would be interesting to assess potential 
confounding factors such as residential area, alcoholic drinking habits and occupation. We 
did not address this in paper II, and this is a limitation. Another limitation was that we did not 
have any matched healthy controls in this study, so we were therefore not able to establish 
that smoking was a risk factor for myositis per se. 
Several studies have demonstrated that smoking is a risk factor for SLE, RA and multiple 
sclerosis and contributes to an increased disease activity and disease severity (see chapter 
1.1.6.5). Furthermore, smoking can trigger immune responses (anti-CCP autoantibodies in 
RA and dsDNA in SLE) and the genetics may contribute to which immune responses that 
may be triggered by smoking [131]. Since 70 % of the newly diagnosed myositis patients 
have ILD [17], and anti-Jo-1 autoantibody positive myositis patients have an incidence of 
ILD that approaches 90% [222], it is tempting to speculate that the immune response in the 
pathogenesis of IIM could be triggered in the lungs by cigarette smoke. In this sense efficient 
anti-smoking information should be given to our rheumatology patients and their families, on 
a regular basis. 
5.3 PAPER III 
The hypothesis to test in this study was that the autoantibody profile in myositis patients is 
associated with a type I IFN signature, as has been reported in patients with SLE. 
We found that the IFN activity in whole blood was significantly higher in patients with 
myositis compared to HCs, and equal to patients with SLE.  We categorized patients into two 
groups, IFN high (n=41, 45%) and IFN low (n=51, 55%), based on the cut off value for the 
average gene expression in HC, and found that patients with DM and IBM had higher IFN 
scores compared to patients with PM. Significantly more patients with DM, regardless of 
autoantibody status were observed in the IFN high compared to the IFN low group. 
Furthermore, we found that almost all patients with multispecific autoantibodies have an IFN 
signature and the IFN score was significantly higher, compared to patients with one or no 
autoantibodies.  
Patients with monospecific autoantibody status were selected (n=30), to determine whether 
the IFN signature was associated with distinct autoantibody specificities. The IFN signature 
was clearly present in patients with monospecificity for autoantibodies against RNA-binding 
proteins (anti-Jo-1 autoantibodies, anti-Ro60 autoantibodies and anti-U1RNP autoantibodies) 
and was absent in most patients with mono-specificity for autoantibodies against other targets 
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than RNA-binding proteins (anti-Ro52 autoantibodies and anti-PM/Scl autoantibodies). 
Furthermore, we found that the IFN score was significantly higher for patients with 
autoantibodies against RNA-binding proteins compared to the patients without these 
autoantibodies. When looking at the whole cohort of 92 patients, only one of the IBM 
patients had detectable autoantibodies targeting RNA binding proteins, and approximately 
half of the patients with DM diagnosis. Therefore, in these subsets other explanations for the 
type I IFN signature must be searched for. 
Next we investigated if sera from IIM patients (n=20) could activate the type I IFN pathway, 
i.e. upregulate the IRG expression in healthy PBMCs. Patients were subdivided into IFN high 
or IFN low, based on the average ex-vivo whole blood IRG induction for all samples. Sera 
from IFN high patients induced IRG expression in healthy PBMCs after 4 h of incubation, 
whereas sera from IFN low patients induced significantly lower IRG induction. None of the 
patients’ sera induced IRG expression at 8 h after serum addition, suggesting that the IRG 
induction is a rapid process. By adding neutralizing IFNAR or anti-IFNα antibodies to sera in 
another subset of IIM patients (n=25), we wanted to determine whether type I IFNs were 
responsible for the observed activation of the type I IFN pathway. The type I IFN bioactivity 
was determined after 4 hours. We found that the IFN bioactivity in IRG high samples, but not 
IRG low, was significantly inhibited by both anti-IFNα antibodies and IFNAR antibodies, 
indicating that IFNα in serum was responsible for most of the observed IRG induction in 
healthy PBMCs.  
To further increase the understanding of the role of type I IFN in pathogenesis of IIM, we 
wanted to explore whether the IFN score correlated to clinical manifestations or laboratory 
variables. The only correlation we found, was a low degree of correlation between the extent 
of the IFN score and disease activity (physician’s global disease activity assessment) for 
patients with DM, but not for the whole group with IIM. There was no correlation seen 
between disease activity measures or laboratory variables and IFN score for PM and IBM. 
This observation may suggest that the IFN activity could possibly be genetically determined. 
One of the limitations in this study could be that the selection of controls and the SLE 
patients were recruited from the Netherlands, while the IIM patients were from Sweden and 
the Czech republic. Importantly all the analyzes were done in the same laboratory. Another 
limitation was that when we divided our 92 patients into subgroups, based on either diagnosis 
or autoantibody mono-and multispecificity the number of patients in each group is small. A 
strength on the other hand, was that the subgroups of myositis were well defined. If we have 
had unlimited blood sample volumes for all 92 patients, it would have been interesting to do 
the IRG induction assay in all 92 samples, to get a more complete view of the IRG induction 
process. A technical limitation was the absence of isotype controls in the experiments with 
anti-IFNα-and anti-IFNAR antibodies. However, we did not have these isotype controls 
available at that time. Moreover, we did not have a specific anti-IFNβ antibody that would 
have enabled us to distinguish between IFNα-and IFNβ-mediated responses. We found that 
patients with autoantibodies against RNA-binding proteins had a significantly higher IFN 
score compared to other patients. However, a causal relationship was not demonstrated and 
was not in the scope of this paper and would need additional studies. ICs containing RNA 
binding proteins could contribute to the IFN signature and other factors in sera e.g. 
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interleukins could also contribute to the IFN activity as well as gene variants in the type I IFN 
signaling pathway. 
In one of our previous studies (abstract and poster ACR, November 2011, Ekholm et al), we 
studied a cohort of 132 myositis patient to assess if the type I IFN activity in sera (using an in 
vitro system with a cell line) correlated with disease activity and/or autoantibody status and 
genetic variables. Patients were categorized into two groups, IFN high (n=13) and IFN low 
(n=119), based on an IFN score. We found a trend for higher self-perceived pain among the 
IFN high patients compared to the IFN low patients (figure 7a). Furthermore, the IFN low 
patients had significantly higher doses of prednisolone compared to the IFN high patients 
(p=0.002) (figure 7b) and this can possibly be explained by the fact that glucocorticoid 
treatment may suppress the type I IFN activity. Significantly more IFN high patients were 
positive for ANA compared to IFN low patients (p=0.001)(figure 7c). This is in line with 
reports demonstrating nucleic acid-containing ICs as endogenous inducers of type I IFN. In 
this cohort there were too few patients in the IFN high group to subgroup the patients into 
MSA specificities. 
 
In conclusion our study underscores that different molecular pathways, such as the type I IFN 
pathway, may predominate in different subsets of myositis, emphasizing the need for careful 
molecular phenotyping of patients to gain better understanding of molecular pathogenesis and 
to improve and individualize treatment. Patients with a multispecific autoantibody profile, 
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patients with autoantibodies against RNA-binding proteins and patients with DM/IBM 
regardless of autoantibody profile, have an activated type I IFN pathway. This indicates that 
the mechanism behind the IFN induction may differ between DM/IBM patients and patients 
with antibodies to RNA-binding proteins, where the latter group has a potential endogenous 
factor that can activate pDCs to produce type I IFN, whereas the mechanisms for IFN 
induction in patients with DM without these antibodies remain to be defined. Gene variants in 
the type I IFN signaling pathway and other factors in sera, such as ILs and NETs could play a 
role. IFNα-blocking drugs are on the market, and clinical trials with anti-IFNα monoclonal 
antibodies suggest beneficial effects in SLE [63], as well as in myositis [65]. Further studies 
concerning the role of the IFN signature in carefully phenotyped myositis patients are needed. 
5.4 PAPER IV 
In this study our hypothesis was that patients with PM and DM have dysregulation of EPCs 
driven by type I IFN and IL-18 similar to other autoimmune diseases, such as SLE. 
We found a significantly lower number of circulating EPCs in patients with PM and DM 
compared to controls. Furthermore, there was a significant reduction in circulating EPCs 
when comparing PM alone vs controls, but not when comparing DM alone vs controls. We 
also demonstrated that EPCs from both PM and DM patients had a significantly lower 
capacity to differentiate into mature ECs, i.e. they had defect monolayer formation, when 
compared to healthy controls. This significance persisted when DM was compared to controls 
(p=0.0350), but not when PM was compared to controls.  
Next, we investigated if sera from patients with PM or DM inhibited EPCs differentiation 
into mature ECs. Patients were categorized into two groups: a) serum that inhibited EPC 
differentiation or b) serum that left unchanged EPC differentiation (based on a cut-off of 90% 
of healthy controls). Significant inhibition of EPC differentiation into ECs compared to 
controls was detected in 25 patients (70%), whereas no significant inhibition was detected in 
11 patients (30%). Of the 25 patients in which sera had an inhibitory effect on EPC 
differentiation compared to healthy control serum, 60% (15 patients) showed improvement of 
abnormal EPC phenotype with IL-18 neutralization and 52% (13 patients) showed 
improvement with type I IFN receptor neutralization. In 2 of these patients (8%) the effect 
was type I IFN receptor specific and in 4 patients (16%), the effect was IL-18 blocking 
specific. However, in 11 patients (44%), the effect was reversed by both strategies and in 8 
patients (32%), the inhibition of EPC differentiation could not be abrogated by any of the 
blocking strategies.  
Furthermore, we found that patients with PM and DM had significantly higher serum levels 
of IL-18, 73 (5-285) pg/ml versus undetectable in controls (p=<0.0001). However, IFN score 
or IL-18 concentration did not correlate with in vitro improvement of the EPC differentiation 
with respective cytokine blockade. Interestingly, sera displaying EPC inhibitory activity had 
significantly higher type I IFN serum activity (i.e. IFN score) than sera that did not display 
inhibition of EPC function. In contrast, significantly higher LDH levels and CRP levels were 
seen in those patients whose sera had a lower type I IFN serum activity i.e. did not inhibit 
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EPC differentiation. This would be in line with results seen in SLE, where type I IFNs inhibit 
CRP upregulation [301]. 
Clinical signs of capillary loss in muscle tissue and microvasculature disturbances in nailfold 
vessels are well known clinical features of both adult and juvenile DM, but the underlying 
mechanisms behind this disturbance of microvessels have not been clarified. Likewise, 
endothelial dysfunction and activation has been described previously in JDM [302]. It was 
shown that VCAM-1 expression was increased in both muscle biopsies and in blood, in 
children with untreated JDM with short disease duration (≤ 2 months) and this supports a 
disturbance in the ECs early in the disease. Activated ECs (but not quiescent ECs) can release 
VCAM-1 resulting in soluble vascular cell adhesion molecule-1 (sVCAM-1) (Lebranchu,Y et 
al,1997), promoting inflammation and muscle tissue damage in JDM [303]. In DM, VCAM-1 
has been inconsistently found in muscle and blood [304-307]. To determine if the EPC 
numbers reflect ongoing EC activation, we decided to evaluate the levels of sVCAM-1 in our 
patient cohort (unpublished data), but we did not see any correlation between sVCAM-1 and 
EPC numbers. This might be because EC damage is not necessarily correlated with low 
numbers, rather it is related to a defect bone marrow synthesis. Furthermore, we did not see a 
correlation with sVCAM-1 and monolayer formation nor did we see a correlation between 
IL-18 and sVCAM-1. The correlation for sVCAM-1 and serum induced EPC inhibition was 
inverse, but not significant. There was no significant statistical difference between serum 
levels of sVCAM-1 in controls and myositis patients (figure 8), but there was a trend for an 
increase in the myositis group. Our control numbers are very low, likely keeping the 
difference from possibly being significant. The median disease duration in our cohort was 2.2 
years and most patients were treated with immunosuppressive treatment, so that might be an 
explanation why we did not see a correlation to sVCAM-1. 
 
 
Figure 8.  Soluble VCAM-1 levels in control and myositis patients.  Serum or plasma levels were measured in 
control (n=6) and myositis (n=53) patients.  p=0.21 between control and myositis patients via Mann-Whitney U-
test. 
There are some limitations in this study, such as not having flow cytometry data, monolayer 
data and the data from sera’s effects on EPC differentiation from the same patients. 
Furthermore, some of the serum samples were from 2004 and these older serum samples 
might compromise the IFN assays, since the IFN molecules are unstable and in general 
difficult to measure directly in humans and freezing and thawing of samples will degrade the 
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IFN molecules. Yet another limitation is that we were not able to make clinical implications 
related to the muscle biopsy findings. This was because we had very few biopsies available 
with staining for CD-31 (endothelial cell marker), and of the muscle biopsies we had, we 
could only detect perifascicular atrophy (as a sign of loss of capillaries) in 3 out of the 36 
patients. We further did correlations between Functional Index 2 (FI-2) [308] (i.e., how well 
patients perform in repetitive muscle endurance) and EPC differentiation, and we did not 
see any significant difference in FI-2 between those patients with impaired EPC 
differentiation and those without impaired EPC differentiation. However, most of our 
patients were at time of blood sampling under treatment with immunosuppressive agents 
and had a median disease duration of 2.2 years, which might explain that no correlation was 
seen. Somewhat surprisingly we found the aberrant EPC differentiation in patients 
diagnosed with DM as well as with PM. This supports a role of the vascular tree in both 
these subsets and is supported by a previous report from our research group where both 
patients with DM and PM had elevated expression of VEGF in muscle biopsies as an 
indication of disturbed microcirculation in muscle tissue [170]. 
The EPC dysfunction seen in both PM and DM patients could possibly contribute to an 
increased risk of thromboembolic events such as deep venous thrombosis (DVT), pulmonary 
embolism (PE), acute myocardial infarction (AMI) and atherosclerosis. An increased risk of 
cardiovascular disease (CVD) has been shown in other autoimmune diseases, including SLE 
[309], RA [310] and SSc [311]. Data on CVD in myositis patients are rare, and have mainly 
focused on atherosclerotic disease [312, 313]. In a case-control study with 798 myositis 
patients an increased risk of DVT and PE was seen in the myositis patients compared to 
controls, especially within the initial years of diagnosis [314]. Another case-control study has 
shown that DM patients are at an increased risk of AMI and ischemic stroke [312]. However, 
further research is needed in this field and the need for thromboprofylaxis may be considered. 
 In conclusion, EPCs isolated from patients with PM and DM were decreased in numbers and 
in function. These findings are likely triggered by the type I IFN/IL-18 axis. Further studies 
are needed to evaluate whether progression of vascular damage, muscle-and organ specific 
outcomes in PM and DM are associated to EPC dysregulation in association with the type I 
IFN pathway. IFNα blocking treatment is currently being explored in PM and DM. It will be 
important to incorporate diagnostic markers of vascular repair and vasculopathy as part of the 
evaluation of therapy and its efficacy. 
 
6 SUMMARY AND HYPOTHESIS 
In this thesis we found that MSAs are important tools for the diagnosis and subclassification 
of IIM and that the line blot assay, which is a rapid and simple method, is a reliable 
alternative to more time consuming procedures such as IPP. Furthermore, in paper II our 
results led us to hypothesize that a gene-environmental (smoking) interaction may prime the 
development of the subphenotype with anti-Jo-1 autoantibodies in myositis patients. In paper 
III we found that the IFN score was significantly higher in myositis patients compared to HCs 
and equal to that seen in SLE patients. Also, the IFN score in patients with autoantibodies to 
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RNA-binding proteins (compared to patients without these autoantibodies) and in patients 
with a multispecific autoantibody status (compared to those patients with one or no 
autoantibodies), and in DM and IBM patients, was increased. A low degree of correlation 
was seen between the IFN score and physician’s global disease activity assessment in DM 
patients. Interestingly, in paper IV we found that type I IFNs and IL-18 play a role in 
inducing abnormal function of EPCs/ECs in both PM and DM in a majority of patients, and 
that the type I IFN serum activity is associated to disruptions in EPC function. 
Apart from our results above, type I IFNs are known to have many immunomodulatory 
functions such as inhibitory effects on the bone marrow precursors, such as EPCs, which may 
lead to defect vascular repair. IFNα can mediate EPC/CAC dysfunction via inflammasome 
upregulation and scewing toward IL-18 production in SLE, and has been shown to be 
antiangiogenic. We also know that the type I IFN can cause T cell/B cell activation and 
autoantibody production. In response to viral or bacterial invasion or RNA-containing ICs, 
pDCs rapidly produce IFNα (figure 9, B). 
Since SLE and IIM are both systemic autoimmune diseases, autoantibodies are common 
features, and accumulating data suggest a role of type I IFN system in both SLE and IIM, it is 
possible to hypothesize that there might be similarities in their disease pathogenesis (figure 
9). Smoking has been related to autoantibodies (dsDNA) in SLE and we have also shown an 
association between smoking and autoantibodies (anti-Jo-1) in genetic susceptible myositis 
patients (figure 9, A). New evidence points toward a plausible role for NETosis, in the 
pathogenesis of SLE. One earlier study suggest a role of NETs in myositis, especially in 
patients with ILD [192]. NETs contain DNA/antimicrobial peptide complexes and are 
released in response to ICs (containing anti-RNP autoantibodies) or bacterial/viral infection 
(figure 9, C). Furthermore, EC activation can elicit NETosis, and NETs in turn can induce 
vascular damage [315] (figure 9, D). NETs may result in exposure to antigenic material, 
toward which autoantibodies can be directed (anti-NET-autoantibody) [315]. This can be 
triggered by IFNα. NETs might also contribute to B-cell activation and autoantibody 
production (figure 9, E). NETs have been shown to enhance IFNα production in pDCs [189, 
316] and IFNα can in turn prime neutrophils for enhanced NETosis (figure 9, F). 
Furthermore, NETs can activate the inflammasome in macrophages to induce the synthesis of 
IL-1β and IL-18, both of which can stimulate NETosis [317] (figure 9, G). We hypothesize 
that NETosis might play a role in the pathogenic mechanism, not only in SLE, but also in 
myositis, at least in some subgroups, in addition to similarities in the type I IFN system, 
presence of autoantibodies, IL-18 and EPC/EC dysfunction. Furthermore, positive feedback 
loops between type I IFN, NETs and inflammasome can perpetuate the inflammation.  
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Figure 9. Simplified schematic illustration of the major findings in this thesis and a potential hypothesis 
associated to these findings. Some symbols are provided by courtesy of  Servier. Red arrows indicate inhibition 
and black arrows stimulation, green arrows indicate a loop of NETs activating pDCs to produce IFNα which in 
turn stimulates NETosis. Purple arrows indicate a loop where type I IFN activates B-cells to autoantibody 
production which in turn stimulates pDCs to produce type I IFN. 
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
In this thesis I aimed to explore and learn more about the pathogenesis in IIM and I conclude 
the following: 
• MSAs more than MAAs are useful tools for the diagnosis and classification of IIM 
• Line blot assay is a reliable alternative method to IPP. 
• Smoking appears to be associated with an increased risk of possession of anti-Jo-1 
autoantibodies in HLA-DRB1*03-positive IIM patients, and we hypothesis that an 
interaction between HLA-DRB1*03 and smoking may prime the development of anti-
Jo-1 autoantibodies. 
• The type I IFN pathway is activated in IIM patients with (i) autoantibodies against 
RNA-binding proteins and in patients with (ii) DM/IBM, regardless of autoantibody 
status and in patients (iii) with autoantibody multispecificity. 
• A low degree of correlation between the extent of the IFN score and disease activity 
was found in patients with DM.  
• IFNα was mainly responsible for the type I IFN activity in myositis patients. 
• PM and DM is associated with dysregulation of EPC phenotype and function that 
may be attributed, at least in part, to aberrant IL-18 and type I IFN pathways. 
Myositis is a heterogeneous group of autoimmune diseases and this thesis has shown that 
different pathogenic mechanisms are likely to contribute to the different subsets of disease. It 
is therefore of utter importance to carefully identify the different clinical subgroups, taken 
into account such factors as the autoantibody profile, the IFN signature and vascular 
endothelial markers. IFNα blocking treatment is already on the market, and could potentially 
be used in patients where an increased IFN-signature is associated with disease activity, 
and/or endothelial dysfunction. 
In paper I, we validated the line blot assay containing 7 antigens. The new line blot strips 
have 9 additional antigens. These 9 new antigens also need to be validated compared to 
IPP/immunoblot and there is an ongoing validation study within Myonet (www.myonet.eu, a 
global multicenter, interdisciplinary research project on IIM, involving clinicians and 
scientists) in collaboration with Professor Johan Rönnelid from Uppsala Akademiska 
Hospital, Uppsala, Sweden. 
In paper II we could not show a correlation between smoking and the risk of myositis per se, 
due to the lack of healthy controls. Further studies are required to address this question.   
There is an international (Europe and USA) case study ongoing, with an epidemiological 
questionnaire concerning smoking and other environmental triggers, to be able to identify risk 
factors for myositis. Also a case-control study in Sweden is ongoing using this 
epidemiological questionnaire.  
All studies in this thesis are cross-sectional. Therefore, to take the results from paper III and 
IV further, it would be interesting to make a study with newly diagnosed IIM patients (with 
autoantibody profiles) and evaluate their IFN-signature, serum IL-18 levels and disease 
activity and treat those patients who have an IFN signature, with IFNα blocking treatment 
and study the effect of this treatment regarding disease activity and effects on the type I IFN 
  
53 
signature and IFNα and IFNβ levels in longitudinally followed patients. Furthermore, it 
would be interesting to enroll myositis patients and study the phenotype and function of EPCs 
and also study the effect of myositis sera in vitro from a longitudinal study, before and after 
treatment (IFNα blocking), with regards to the IFN signature and IL-18 levels, and also make 
clinical correlations to disease activity and muscle endurance. In such a study it would be 
very interesting to study muscle biopsies, before and after treatment, to detect possible 
vascular rarefication and correlate this to the IFN signature, IL-18 levels and disease activity. 
Similar to studies in JDM, it would be interesting to address the role of the adhesion 
molecules, such as VCAM-1, in newly diagnosed IIM patients as compared to those with 
longer disease duration. The different subgroups in such a study would need to be carefully 
defined according to disease duration, autoantibody status, disease activity, smoking status 
and HLA-typing.  
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